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RÉSUMÉ - Objectif de l’étude : Nous avons déterminé la valeur prédictive de la troponine T 
cardiaque de haute sensibilité (TnTc-hs) chez les patients âgés et très âgés afin de 
diagnostiquer plus précisément les événements coronariens aigus, en particulier chez les 
patients atteints de maladies concomitantes. 
Matériels et méthodes:  
Nous avons évalué rétrospectivement 6 977 dossiers médicaux de patients âgés de ≥ 65 ans 
admis au CHUS CIUSSS-Estrie ayant eu une mesure en série TnTc-hs. Le premier échantillon 
sanguin pour la mesure de TnTc-hs qui a été recueilli au moment de l'admission a été pris en 
compte. Les patients âgés ont été regroupés en trois groupes d’âge : les patients âgés de 65 à 
74 ans (jeunes âgés), les patients âgés de 75 à 84 ans (âgés) et les patients âgés de 85 ans et 
plus (très âgés). Ensuite, ils ont été divisés en 3 catégories selon le tertile TnTc-hs concentration 
avec tertile 1 (0-14 ng / L = niveau bas), tertile 2 (15-31 ng / L = niveau modéré) et tertile 3 (≥32 
ng / L = niveau élevé). Dix-sept comorbidités ont été identifiées ultérieurement dans notre 
échantillon. Les patients ont été regroupés en quatre catégories selon la présence de 
comorbidités avec : quartile 1 (une ou deux comorbidités), quartile 2 (trois comorbidités), quartile 
3 (quatre à cinq comorbidités) et quartile 4 (≥ 6 comorbidités). 
Résultats :  
Trois mille quatre cent trente-neuf patients de sexe masculin (50,4%) ont été inclus dans l'étude. 
Deux mille quatre cent quatorze patients ont eu six comorbidités ou plus (35,4%). Pour notre 
cohorte, dont l'âge moyen était de 78,3 ans, le taux TnTc-hs était de 79,9 ng / L. Chez les deux 
sexes, la valeur de la troponine dans tous les groupes d'âge, avec tous les types de 
comorbidités, était remarquablement élevée. En outre, l’odd ratio (OR) de la dose élevée et de 
la dose modérée de troponine a été trouvéle plus faible chez les groupes jeunes âgés et âgés (p 
< 0,001). L'augmentation de l'âge et le nombre de comorbidité pourraient augmenter les 
chances d'avoir des taux élevés de TnTc-hs (p <0,001),mais étonnamment, en ce qui concerne 
l’OR ajusté, si l'on considère une année de vieillissement et une comorbidité en continu, les 
troponines surélevées sont influencés plus significativement par la comorbidité, 
comparativement au vieillissement (p <0,001) 
Conclusion :  
En ce qui concerne l’étude actuelle, une élévation globale des valeurs de TnTc-hs dans tous les 
groupes de comorbidités a été détectée. De plus, bien que l’âge avancé puisse être associé à 
une élévation de TnTc-hs (OR =1,07, p<0,001); en revanche, l’élévation de la troponine 
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cardiaque résulterait plus de comorbidités préexistantes (OR=1,31 pour le groupe jeune âgé et 
OR=1,22 pour le groupe âgé, p <0,001). Par conséquent, une valeur élevée de TnTc-hs devrait 
être considérée comme étant d’origine pathologique et l’éthologie spécifique devrait être 
recherchée 
Mots-clés: TnTc-hs, patients âgés et très âgés, comorbidités. 
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Abstract. – A high level of troponin correlates significantly with the risk of death or recurrence of 
myocardial infarction. However, most of these studies have been obtained in middle-aged 
people. It is considered that ageing is associated with increased troponin levels. This can be a 
major drawback for the stratification and diagnostic of acute coronary syndrome in elderly 
patients. Our study was designed to determine the predictive value of high-sensitivity cardiac 
troponin T (Hs-cTnT) in the elderly and very elderly patients and mainly in the presence of 
concomitant diseases. 
Materials and Methods: We retrospectively evaluated 6 977 medical records of patients aged ≥ 
65 years and admitted for patients admitted to the hospital for chest pain. Three age groups 
were formed: patients aged 65 to 74 years (young-old), patients aged 75 to 84 years (old) and 
patients ≥85 years old (old-old). Three categories were formed according to the Hs-cTnT levels: 
0-14 ng/L, 15-31 ng/L and ≥32 ng/L. Seventeen comorbidities were identified and patients were 
grouped into four categories according to the number of comorbidities: 1 or 2 comorbidities, 3 
comorbidities, 4-5 comorbidities and ≥ 6 comorbidities.  
Results:3 439 male patients (50. 4%) were included in this current study among which 2 414 
patients had six or more comorbidities (35.4%). For our cohort, whose average age was 78.3 
years, the Hs-cTnT level was 79.9 ng/l. In both sexes, the troponin value across all age groups, 
with any types of comorbid disease excluding any cardiac diseases, was remarkably high 
compared to the normal troponin values (p<0.05). Our results also demonstrated that the Hs-
cTnT levels increased in the presence of comorbidities independently of their number (p<0.05). 
In the old-old group the troponin levels decreased even when comorbidities were present 
suggesting that age is not the determinant factor in the troponin increase.  
Conclusion: Advanced age could not be associated to an elevation of Hs-cTnT; in contrast, 
cardiac troponin elevation was the result of pre-existed comorbidities independently of their 
number. Increased troponin level in elderly should always be considered as pathological and a 
specific etiology searched.  
Key words: Hs-cTnT, elderly and very elderly patients, comorbidity 
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INTRODUCTION 
Over the next thirteen years, the world's population is estimated to rise from 7.6 billion (in mid-
2017) by more than one billion people, reaching 8.6 billion in 2030, rising to 9.8 billion in 2050, 
and 11.2 billion in 2100(UN, 2015). The number of people 60 years old and over is estimated to 
be 962 million, 13% of the total population in mid-2017.  The annual growth rate for this age 
group has been estimated approximately three percent(UN, 2015).According to the United 
Nations report, the world’s population is dramatically continuing to become old.  Almost, all 
countries have shown an increase in number and percentage of elderly in their population. In 
other words, the number of people aged 60 years and older has increased significantly in most 
countries and regions in recent years and is expected to increase rapidly in the coming decades. 
The fastest growth rate of the elderly between 2000 and 2015 has been demonstrated in high-
income countries and is expected to show the same between 2015 and 2030(UN, 2015). It is 
expected that the growth in number of elderly will increase rapidly between 2015 & 2030, in 
upper-middle-income countries too.   
Considering this projection, between 2017 and 2030, the number of aged people 60 years and 
over will increase by 56 per cent, from 962 million to 1.4 billion, and by 2050, the world 
population of elderly is projected to more than double its size in 2017 (Fig. 1), reaching nearly 
2.1 billion, and will reach to 3.1 billion in 2100. 
 
Figure 1. Number of people aged 60 or over; World, developed, and developing country, 1950 – 
2050.Source: UNDESA, World Population Ageing 2011 (2012; forthcoming), based on UNDESA 
Population Division medium projection scenario, World Population Prospects: The 2010 
Revision. 
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This report also projects that, the growth rate of population aged 80 or over, who is called the 
″oldest-old″ persons, will increase faster than the rate of older population (Figure 2) 
 
Figure 2. Population aged 60-79 years and aged 80 years or over by development group, 2000, 
2015, 2030 and 2050, Data source: United Nations (2015). World Population Prospects: The 
2015 Revision 
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In this way, the oldest-old population, from 137 million in 2017 will reach to 425 million in 2050, 
and it is estimated that in 2050 having more than tripled in numbers compared to 2017 (Fig.3).  
 
 
Figure3. The expected percentage change in the world's elderly population, by category, from 
2010 to 2050.Reconstructed from:United Nation, world population prospect,Available 
at:https://www.un.org/development/desa/en/news/population/world-population-prospects-
2017.html 
The number of people reaching 80 or over will exceed 909 million in 2100, showing the increase 
by almost seven times its value in 2017. 
In the United States of America (USA), the percentage of people aged 60 and over in 2015 has 
been calculated as 24.6%, and for years 2050 and 2100, it has been projected as 36.2% and 
44.1% of the population respectively(UN,2015). 
For Canada, the proportion of the population aged 65 and over grew from 14.1% in 2006 to 16.6 
% in 2016(Statistic Canada,2017). For the first time, the number of Canadian seniors aged 65 
and older surpassed the persons under 15 years of age in 2015 (Statistic Canada, 2015).  The 
projected growth scenario is expected to be further increasing the future population of the elderly 
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in Canada. According to the United Nations, the percentage of aged people for years 2050 and 
2100 in Canada will reach to 43% and 50.4% respectively(UN, 2015). 
According to three demographic projections named low-growth, medium growth & high growth 
scenarios, referring to population growth rate that has been presented by Statistic Canada 
(Fig.4), both overall numbers & proportions of people aged 80 years and over are rising rapidly 
in Canada in the near future. 
 
Figure 4.Median age observed (1981 to 2009) and projected (2010 to 2061) according to three 
scenarios, Canada. Available at:http://www.statcan.gc.ca/pub/91-520-x/2010001/ct010-eng.htm. 
The main issues that emerge 
Obviously, dramatic growth in numbers and proportions of the senior population, not only puts a 
heavy pressure on health systems and requires further demand for medical services, but also 
increases the risk of diseases associated with age. 
The main reasons assigned for accompanying of the growth of the ageing population and 
increase of life expectancy can be concluded as: (1) Prevention, treatment and control of the 
transmission of communicable diseases as a result of advances in medicine, adoption of modern 
technology in public health and public health services development. (2) Implementation of 
successful strategies for pandemic control. (3) Possible elimination of large-scale wars. (4) 
Improvement of standards of living and (5) Revolution in favor of agricultural systems (food 
production and food security), (Giannitsis,et al., 2010). 
It is acknowledged that the elderly patients are poorly represented in clinical studies. It is 
estimated that the older individuals were excluded up to 35% in the published studies(Shenoy et 
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Harugeri,2015,Lee, ,Alexander, Hammill, Pasquali, Peterson,2001 ,Masoudi, et al., 2003), which 
contributes to lack of knowledge and understanding of the process that may contribute in 
developing age-related diseases that undermines the diagnostic criteria for this group. The cost 
of ignoring old people, particularly very old people from research trials, not only threatens their 
well-being by lacking of knowledge and understanding of the process that may contribute in 
developing age-related diseases that undermines the diagnostic criteria for this age group, but it 
can significantly influence physician's decision making process. 
Physiopathology of ageing 
Although there are no tools to define ageing precisely from the medical perspective, it has been 
defined as a sum of all changes that occur in living organisms, which appears over time, and 
inevitably lead to senescence (Levine, 2012).Actually, aging is defined as a subtle, progressive 
and irreversible process which appears slowly during years with different rate among people 
(Roger, 2007) that result from a continuous biological accumulation of many different types of 
damages caused by molecular defects that augment in cells and tissues.  
Although many theories exist that explain the aging, there is no a single theory that defines the 
ageing process reasonably & comprehensibly (Hayflick, and Moorhead, 1961)Amongst different 
possible theories that explain the mechanism of ageing, Dr. Hayflick et al., suggested a 
phenomenon, which refers to a restriction for cellular division in human, known as ″The Hayflick 
Limit Theory″(Hartman,1956). According to this theory, this limitation may result from several 
different factors including genetic misconstruction as telomere shortening, activation of different 
oncogenes as well as aberrations in genetic pathways, release of free radicals during oxidative 
stress conditions that raise with aging that leads to intracellular damages, abnormally elevated 
inflammatory markers and increase in apoptosis(programmed cell death). In 1956, Dr. Denham 
Harman(Erbas and Sekerci, 2011)proposed the free radial theory of ageing, considering ageing 
as a consequence of imbalance between the productions of Reactive Oxygen species (ROS) or 
oxygen free radicals and antioxidant protection systems. A free radical is defined as any highly 
reactive atom or molecule that contains at least a single unpaired electron in an outer shell 
mainly produced as mitochondrial respiration (Cheeseman and Slater, 1993; Wennberg, 1999). 
Based on this theory, advanced accumulation of oxidative DNAcauses cellular damage that is a 
synergistic factor leading to aging. 
6 
 
 
However, ageing-induced changes could be observed in essentially tissues, organs and organ 
systems. These changes not only lead to a variety of consequences in tissue and organ 
dysfunction but also influence clinical presentation of diseases.  
Considering the genetic and environmental influence on human aging, there are no specific 
ages at which people become exactly aged or very aged. By tracking a sample of subjects from 
birth,it can be proven that the risk of developing a disease would vary as the birth cohort aged, 
thus, confirming the role of aging as an important and non-modifiable contributor in many 
diseases. It can be derived that it is inevitable to define ageing according to chronological 
models. Therefore, it has been accepted as a convention, an individual aged 65 year or more be 
called as the elderly(Batchelor et al., 2000; WHO, 2012).   
Age related changes could be aggravated by specific comorbidities or pre-existingconditions. 
Consequently, the presence of comorbidities with ageing may affect functioning, quality of life 
and mortality. These conditions potentially can increase the risk when comparing with the 
condition that might be expected in the younger adults(CIHI, 2011).In other words, comorbidities 
that mostly accompany in aged people can mainly lead to a worse prognosis and consequently 
increase of both mortality and morbidity of acute heart conditions in elderly. Therefore, ageing 
and comorbidities are two conditions that have strong relation in medical practice. 
Almost three quarters of Canadians and Americans seniors over 65 have at least one to three 
chronic conditions respectively (Alami,Fanf,Song,Nacamuli,2003; LeRoyet al.,2014). 
A number of different processes are more associated with ageing, and have direct impact on 
cardiovascular health, function, and clinical decision making relative to heart conditions. Ageing 
process involves progressive and often functional impairments in across multiple organ systems. 
As a result, this can significantly lead to major morbidity and mortality and affect the 
pharmacokinetics and pharmacodynamics of medication in the elderly(Kajstura, 1996; Schwartz, 
2007). 
The main changes in the heart structure  with ageing result in loss of cardiomyocytes, due to 
necrosis or apoptosis (Lie et al.,1988), which stimulates the hypertrophy of the remaining 
cardiomyocytes, increase of the connective tissue accumulation (fibrosis), and amyloid 
deposition in very old individuals (Gerstenblith,1977).  Loss of cardiomyocytes can cause 
excessive cells stretching and atrial wall stiffening impose an increased vascular load, leading to 
left ventricle walls thickness(Lakatta, 2007). 
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In the elderly, due to an increased amounts and concentration of collagen and decrease levels 
of elastin in the arterial wall, arterial compliance is normally decreased (Yu and Chung, 2001; 
Maruyama, 2007).In the above population, the blood vessels, the endothelial function is also 
abnormal because the production of nitric oxide (NO) is reduced by decreasing NO-dependent 
dilation. In addition, other bimolecular changes such as increases in specific matrix 
metalloproteinase, transforming growth factor-beta 1, and angiotensin II, contribute to 
endothelial dysfunction (Martz et al., 2000). Moreover, NO bioavailability decreases with 
aging(Van der loo et al., 2000).Subsequently, it has mostly been assumed that the reduction of 
bioavailable nitric oxide is secondary to increased oxidative stress during ageing (Pugh,et al., 
2001; Webb, et al., 2005). The structural and functional changes in the heart with aging have 
shown in figure 5. 
Stiffening of the great arteries may promote an increase in systolic blood pressure, a decrease in 
diastolic pressure and widening pulse pressure(Yu, B. P., and Chung, 2001). Meanwhile, the 
effect of aging on the other systems may affect cardiovascular system that could be exemplified 
by aged-induce decrease in the testosterone production of the endocrine system resulting in 
changes to distribution of the cardiac contractile proteins (Tsang,et al., 2002). 
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Figure 5.Ageing induced changes in cardiovascular system in healthy subjects.Modified from 
Lakatta, EG: Cardiovascular regulatory mechanisms in advanced age. Physiol. Rev 73: 413–
465, 1993 
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The main age-associated changes in the cardiovascular system that contribute in morbidity and 
mortality could be summarizedas follows:  
➢ The cardiac mass in elderly usually is increased(Pearson, ,et al.,1997) 
➢ Endothelial dysfunction which enhances vasoconstriction 
➢ Heart rhythm disorders (Hees, et al.,2004) 
➢ Increased systolic blood pressure, even if they are normotensive (Beck,2000) 
➢ Left ventricular hypertrophy as excess thickening of the left ventricle 
➢ Arterial stiffness as an increase in both systolic blood pressure & pulse pressure 
➢ Diastolic ventricular dysfunction (early diastolic filling of the ventricles is reduced), that 
could deteriorate diastolic filling abnormalities (Yazdanyar et al.,2009) 
➢ Decreased cardiac reserve (the heart cannot achieve its maximum capacity when 
needed) 
➢ The heart pumping would be in an arrhythmic fashion because the cardiac action 
potentials are prolonged 
➢ Cardiac-induced renal dysfunction(WHO,2010)(inability to maintain composition and 
volume of body fluid) 
The effect of ageing on the heart could be exemplified by referring to increased occurrence of 
acute coronary syndrome (ACS) or acute myocardial infarction (AMI) inthe elderly. In spite of the 
fact that aging alone should not necessarily be considered linked to ACS or AMI, the majority of 
epidemiological studies concerning AMI or ACS have been significantly demonstrated that 
ageing is associated with a sharp rise of these cardiac diseases(Orimo, et al., Pal Yu, et 
al.,Yu,2006;Roger,2007).  
The correlation between the physiological processes of aging and age-related pathological 
processes has been demonstrated (Extermann, et al., 2005, Carroll and Miller, 
2010).Consequently, aging may alter the clinical manifestation, response to treatment, and 
outcomes of diseases. Therefore, the observations regarding the performance of a clinical trial in 
accordance with the young population may not apply in elderly patients. 
It is important to identify with precision the major causes of death in the elderly and the extreme 
elderly as well, in order to change mortality rates among the older population.Given the 
differences in physiological reserves, comorbidities, functional capacity, and geriatric 
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syndromes, the elderly reveal a heterogeneous population(HALE project, 2004).These criteria 
may influence the clinical symptoms, even may modify the clinical consequences. As a result, it 
seems inappropriate to assume that the elderly benefits of the same clinical approach as for the 
younger population. Furthermore, elderly patients may not represent the same predetermined 
outcomes in paraclinical investigations. 
In conclusion, risk of developing morbidity and mortality of ACS or AMI has been significantly 
increased with aging (WHO,2015). The impact of ACS or AMI among older adults has been 
integrated by reducing homeostatic reserves, increasing prevalence of comorbidity, increasing 
polypharmacy and creating more complex social issues. 
Cause-specific mortality in elderly 
The global outbreak of non-communicable diseases is mainly related to aging.  Although there is 
a worldwide difference to present the secondary causes of death in the elderly among stroke, 
cancers or respiratory diseases, there is a global consensus regarding the role of Ischemic heart 
diseases (IHD) as a main cause leading to death among older people (HALE project, 
2004,WHO,2015). 
 
Figure6. The 10 main global mortality causes in people aged 60-69 years, in 2015, 
IHD=Ischemic Heart Disease, COPD=Chronic Obstructive Pulmonary Disease,L&URTC=Lower 
and Upper Respiratory Tract Cancers,DM=DiabetesMellitus, LRI=Lower Respiratory Infection, 
TB=tuberculosis, LC=Lung cancers, RD=Renal Diseases,Modified 
from:http://www.who.int/gho/mortality_burden_disease/en/ 
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Figure 7. The 10 main global mortality causes in people aged 70 years and over, in 
2015,IHD=Ischemic Heart Disease, COPD=Chronic Obstructive Pulmonary Disease, LRI=Lower 
r respiratory Infection, DM=Diabetes Mellitus L&URTC= Lower and Upper Respiratory Tract 
Cancers, HHD=Hypertensive Heart Disease, RD=Renal Diseases, CRC=Colorectal 
CancerModified from 
http://www.who.int/gho/mortality_burden_disease/causes_death/top_10/en/ 
 
CHD is the most common cause of death worldwide, in both men and women(Scarborough, 
Wickramasinghe, Bhatnagar, and Rayner, 2011; Lloyd-Jones, Gersh. 2008; Mozaffarian, et al., 
2015). Despite recent progress in the prevention and treatment of cardiovascular disease with 
adopting a healthy lifestyle such as regular exercise and physical activity, developing healthy 
eating habits or a balanced diet to have a healthy weight, that could help to reduce the rate of 
CHD in elderly (WHO,2008;Statistics Canada,2015;Ibanez, et al,2017). However, cardiovascular 
diseases are reported as the main cause of death in the elderly in all economic levels (low, 
middle, & high income) of many countries (Statistics Canada,2012). 
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Figure 8.Leading contributors to burden of disease in people aged 60 years and older in 2010—
DALYs (million) by cause and World Bank income.DALYs=disability-adjusted life years. 
CVD=cardiovascular and circulatory diseases. MND=mental and neurological disorders, 
combining the IHME GBD mental and behavioral disorders and neurological disorders groups. 
The main causes of death in elderly in Canada 
Given that the Canadian population is aging, it can be expected that in the near future an 
increasing number of people with heart disease will be observed. In Canada, the highest 
incidence of heart disease has been reported with the groups aged 65-79 and 80 and older, 
15% and 24% respectively (Alexander, et al., 2005; WHO, 2017). The age adjusted incidence of 
acute myocardial infarction is 10 times higher in aged group 65-74 compared to aged group 35-
44, amounting to 70,000 acute myocardial events yearly.  According to statistics Canada, heart 
diseases are the second leading cause of death for people aged 65 years and over (Fig.9). 
0
20
40
60
80
100
120
140
160
180
200
High-income contries
Low income and middle-income
countries
13 
 
 
 
Figure 9.Death Database, CANSIM Table 102–0561., HD= Heart Diseases, CLRD=Chronic 
Lower Respiratory Disease, Modified from: Vital Statistics. Modified 
from:http://www.statcan.gc.ca/pub/82-625-x/2017001/article/14776-eng.htm 
 
Epidemiology of acute coronary syndrome 
About 33% of all ACS events happen in patients aged over 75, and they give reason for almost 
60% of all-cause mortality (Savonitto, Morici, and De Servi, 2014).The worldwide fatality rate of 
ACS in 2015 has been estimated 7.6 million deaths per year (Braunwald, and Bonow, 
2014).Elderly patients, who are suffering from ACS, make a prominent part of hospitalized 
patients; this will be significantly increased in the near future(Saunderson, et al.2014).  ACS 
accounts for 60% of hospital admission and 85% of deaths in patients aged over 65 years 
(Roger,et al., 2012). ACS-induced mortality rate in patients aged over 85 years is at least three 
folds higher than the age group under age of 65 years (Arnold, et al., 2005). 
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Figure10.Prevalence of current diseases in the united states,data are percentages.AF(Atrial 
Fibrillation),BP(blood pressure),CVD(cardiovascular diseases),PAD(Peripheral Artery 
disease),From:Douglas L. Mann,et al.Braunwald’s Heart Disease : A Textbook of Cardiovascular 
Medicine ,2015,ISBN: 978-1-4557-5133-4 
Coronary heart disease (CHD) accounts for more than half of all cardiovascular events in both 
men and women, under the age of 75 in the United States(Lloyd-Jones, et al.,2009). Regardless 
of race or gender, the elderly will face with significant increases in incidence of CHD with 
advancing age (WHO,2011).In women compared to men, not only the incidence of CHD takes 
place 10 years later, but also the occurrence of more life-threatening conditions like sudden 
death or acute MI  delay for at least 20 years(Yusuf, Reddy, Ounpuu, and Anand,2001). 
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Figure 11.Prevalence of coronary heart disease in the US by age and sex (National Health and 
Nutrition. Examination Survey: 2009–2012).Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute 
AMI is recognized for 40% and 50% of the 17 million annual causes of CVD death in the world 
(PHIC, 2009; Fitchett, et al., 2011). Advanced age notably associated with increased incidence 
of AMI. In the USA, more than 60% of hospital admissions are due to AMI in people who are 65 
and older(Harman, 1956). Incidence of AMI is increased 10-fold greater in patients 65 to 74 
years of age compared to those 35 to 44 years of age, and continuously have higher death rates 
in patients over the age of 65 years (Hayflick, 1961, Orimo,2006). Up to the age of 80, the 
prevalence of AMI appears in both sexes in equal frequency, but then it will be more common in 
women (Roger,2012). 
In Canada, ACS is responsible for 19,000 deaths annually, whereas it has been estimated the 
AMI prevalence is almost 70,000 per year (Welsh, Travers, Huynh, and Cantor, 2009). Among 
Canadian adults aged 65 to 74 years, the prevalence rates of heart disease have been 
estimated to be 14.8%, it reaches 22.9% over aged 75 years (Benjamin, 2017; Mozaffarian, et 
al.,2016). 
Mortality of ACS and AMI, in persons who experience it for the first time is estimated 34% and 
15% respectively, and it is projected that, every 42 seconds, an American will suffer from MI 
(Mozaffarian, et al., 2015). Coronary heart disease accounts for 51% of all cardiac death in the 
USA (NHLBI, 2007). 
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In 2013, CHD was accounted for one-seventh of all deaths among the Americans. It has been 
computed that one American is attacked every 34 seconds by acute coronary events and one of 
these patients dye every 84 seconds (ARIC,2004-2009). With increasing age, the prevalence 
rate of AMI, appears to be rising, so that in adult aged 65-74 years compared to 35-44 age 
group, it is approximately seven times higher (Goodman, et al.,2009). The estimated median age 
at first MI in men and women is 65.1 and 72.0 years respectively (Kolansky, 2009). 
The economic burden of acute coronary syndrome in elderly 
The impact of age on ACS has made its significant economic burden in elderly (76). 
Hospitalization rates for ischemic heart disease are increased with advancing age. ACS as the 
most common condition related to ischemic heart disease in the USA, is significantly common 
condition associated with heart disease leading to hospitalization in the USA(PHAC,2009;Yusuf, 
Reddy,Ounpuu, and Anand,2001;Mozaffarian,2015).In General, the economic burden of ACS 
has a direct impact in the increase cost of health care. It has been reported the US spends more 
than 150 billion dollars annually for their total direct medical expenditures(CIHI,2017). It has 
been shown that the elderly with AMI are the biggest users of professional health 
services(Maton,1997;Cohen,2014).  In Canada, the average cost of AMI in elderly patients, in a 
6 year care-period, has been estimated $28,169 per patient (Ross,1993).  There is a significant 
need to distinguish the ACS and AMI utilizing cardiac risk- stratification in order to reduce the 
cost of the health care system. 
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Risk factors for acute coronary syndrome 
Coronary heart disease is usually caused by atherosclerosis, which creates a plaque resulting 
from migration and accumulation of macrophages (foam cells) inside arterial walls (chronic 
inflammatory response(Hansson, and Hermansson, 2011). Atherosclerosis induces intimal 
smooth muscle cell proliferation (intimal hyperplasia) constructing a bump called atheromatous 
(fibro-fatty) plaque (Libby, 2002; Lind, 2003). The growing bump on the arterial walls, with 
decreasing cross-sectional area of the vessels, contributes to partial or complete blockage of the 
narrow coronary arteries (Wagenknecht, et al., 2009; Kim, et al., 2011), this leads to 
disturbances in coronary circulation and therefore insufficient oxygen supply to the heart muscle. 
In other words, the atherosclerotic plaque may develop slowly and encroach into the arterial 
lumen, or turn vulnerability into thrombosis yielding obstruction. 
The established atherosclerotic plaque consists of two main parts (Wang, and Bennett, 2012): 
1) A fibrous cap that is composed of vascular smooth muscle cells and their major secretory 
products (such as collagen and elastin), inflammatory cells (such as macrophages, T 
lymphocytes, dendritic cells, and mast cells) 
 2) A "necrotic" core which is surrounded by fibrous cap, and includes intra cellular and 
extracellular lipids, foam cells, and debris.   
A developed atherosclerotic plaque contains high concentrations of calcium salts as well (Roger, 
et al., 2012). 
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Figure12. A cross-sectional distribution of left coronary artery bifurcation that illustrated severe 
atherosclerosis. A fibrous plaque in the left circumflex (Left),a complicated plaque with a 
nonocclusive thrombosis in the left marginal artery, a branch of the circumflex artery which 
called obtuse branch, (Right).Abbreviations: C:contrast in the lumen, Ca: calcification, T: 
thrombosis. From: Pierre Théroux, Acute Coronary Syndromes, 2nd edition, A Companion to 
Braunwald’s Heart Disease,2011,C H A P T E R 6,page 42 
Although atherosclerosis plaque stability results from cap thickening and inflammation degree of 
the capsule, plaque instability and or its rupture refers to vascular smooth muscle cell apoptosis, 
that result in cap thinning, segregation of collagen and extracellular matrix (Eggers,et al.,2008) [ 
as structural and biochemical supporters of surrounding cells].  
The vascular endothelium has a crucial role to maintain vascular integrity. Therefore, age 
associated vascular endothelial dysfunction; vascular stiffness and inflammation contribute to 
rise in the incidence and prevalence of CHD with advancing age in both sexes(Virmani,et al., 
2006). The role of atherosclerosis has been proven over many years in clinical medicine as a 
single largest suspect and main cause of coronary artery diseases that predispose to death and 
disability with the passing of time (Berenson,et al., 1998). 
It has been demonstrated that there are two different fundamental mechanisms for thrombosis 
on the plaques as superficial erosion of the endothelial monolayer and deep endothelial fissuring 
which involves the developed plaque(Bolton, and Rajkumar, 2011). 
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Figure 13. Rupture of the fibrous cap (left) triggers two-thirds to three-quarters of all cases of 
fatal coronary thromboses. Superficial erosion (right) takes place in one-fifth to one-quarter of 
fatal coronary thromboses. (Modified from:Libby (2008).The molecular mechanisms of the 
thrombotic complications of atherosclerosis 
Coronary atherosclerosis has been predisposed as an underlying condition that is developing 
during childhood and adolescence(Maton, et al., 1994). In cardiac myocytes, with developing 
atherosclerosis, cellular senescence will be observed (Gale, et al., 2011). 
As a result, most individuals with age progression have evidence of coronary atherosclerosis. 
Today, it is well recognized that atherosclerosis has an early and long phase of development, 
which begins in infancy (Fox, et al.,2005). In other words, ACS in elderly compared to younger 
counterparts generally has a poorer prognosis (Eagle, Lim, and Dabbous,2004;Rosengren,et al., 
2006; Elbarouni,et al., 2009). Moreover, ageing as a verified risk factor has been determined for 
CHD development that is remarkable to predict short term and long term mortality in the most 
inclusive of ACS risk models (Wilson, et al.,1998;Gale, et al.,2008;Farhat,et 
al.,2008;Kozieradzka,et al.,2011).Consequently, it can be deduced that the prevalence of 
coronary artery diseases increases with advanced age. However, it is now well recognized that 
among symphony orchestra players that create atherosclerosis, ageing has a non-modifiable 
role(Niemann, et al.,2011) that makes a prominent ear-splitting noise in this orchestra. 
Among the identified atherosclerotic risk factors including: LDL cholesterol, HDL cholesterol, 
triglycerides, systolic blood pressure, male sex, family history of early MI, diabetes mellitus, and 
smoking, ageing has a significant rolethat independently promotes the development of 
atherosclerotic disease even if all other mentioned risk factors could be controlled (Saunderson, 
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et al.2014,Mueller,1991).Considering that age is included in the main risk-related fashions, 
consequently older people are put as high risk based on age alone (Naylor,2003). 
Biomarkers of acute coronary syndromes in the elderly 
Biomarkers or biological markers are defined as cellular, biochemical, molecular or anatomic 
modifications that are empirically measurable in order to detect the process related to normal or 
particular health conditions. These tests can assist in understanding the evolution of diseases, 
risk factors of diseases, monitoring responses to therapeutic interventions in a culture medium 
such as blood serum or tissue extract (Abernethy, et al., 2001, Morrow, & De Lemos, 2007; 
Wallace, et al., 2008).  In other words, in clinics, the use of biomarkers are a practical and 
dynamic approach in order to study the disease characteristics with referring to screening, 
diagnosis, prognosis and monitoring medical interventions. 
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The characteristics of an ideal biomarker for acute coronary events 
There has been serious debate among researchers, clinical chemist and physicians to introduce 
advanced screening strategies. In order to identify patients who are initially free of CHD 
manifestations but at risk of acute coronary events, the clinicians require safe, accurate, 
affordable, and reliable biomarker. 
A novel and standard cardiac biomarker has to be measured easily, with added new information 
that can be useful in patient management (Rosalki, 2004). In addition, the main feature of each 
biomarker has to consist of a release kinetic model from specialized or individual cells, i.e. with 
specificity and sensitivity. 
According to the FDA (Food and Drug Administration) (Lippi, 2015), the feature of an ideal 
cardiac marker is as follows: 
1. Specific: 
 high serum ratio in myocardium 
 not even pathologically found in non-cardiac tissue 
 Show appropriately a clear distinction for different pathogenesis of cardiac 
involvement (acute to chronic, necrosis, hypertrophy, rhythm) 
2. Sensitive: 
 Zero measurement baseline (standard) 
 indicator of early onset and reversible cardiac injury 
 instantaneous release if there is an injury  
3. Predictive: 
 Long serum half-life in circulation (indicates that it is reversible) 
 degree of release is proportional to degree of injury 
4. Performance: 
 must be accurate, simple, inexpensive and fast detection in all clinically 
relevant markers 
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5. Provide a clinical and paraclinical bridge 
6.  Readily available and noninvasive  
History of cardiac biomarkers,from past to present 
Despite the fact that there has been a great biomedical debate for decades over the ACS 
diagnosis (Dolci, & Panteghini, 2006), the acceleration of cardiac biomarkers development has 
come to an almost complete agreement to introduce a relatively perfect cardiac biomarker 
(LaDue, Wroblewski, & Karmen, 1954; Karmen, Wroblewski, & LaDue, 1955). 
 
Traditional cardiac biomarkers of acute coronary syndromes 
The primary biomarkers applied to identify acute cardiac ischemia consist of aspartate 
aminotransferase and lactate dehydrogenase isoenzymes. 
1. Aspartate aminotransferase (AST) 
In 1954, aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT) 
was presented as first cardiac biomarkers to determine predictors of coronary events (Henry, 
ChiamoriI, Golub, Berkman, 1960;Wilkinson, Baron, Moss, & Walker, 1972), technically 
improved in years later (Cabaud, Leeper, & Wroblewski, 1956; Wroblewski, Ruegsegger, & 
Ladue, 1956), and for many years, that played the most important role to predict acute coronary 
events (Ruegsegger,  Nydick, Freiman & Ladue, 1959;Ladenson, 2007).  Increased AST levels 
can be observed 3–4 hours after acute coronary injury in circulation provides the maximum 
blood levels in 15–28 hours and then returns to normal levels during 5 days(Wroblewski, 1955). 
Although AST has a great sensitivity to detect acute coronary injury, it is not an ideal 
cardiacbiomarker due to its existence in the liver, skeletal muscles, brain and kidneys, that gives 
significantly a low specificity (Lee, 1986, Saunderson, 2014). 
2. Lactate dehydrogenase (LDH) 
Elevated level of lactate dehydrogenase (LDH) and its isoenzyme (LDH-1) have been 
demonstrated among patients with AMI(Rozberg, 1962; Penttilä, et al., 2000), in 1956. 
Increased blood level of LDH and LDH-1(LD-1) are observed 5–10 hours after AMI, reaches 
maximum at 2.5 to 6 days and returns to baseline in 12 days (Blomberg, Kimber,& Burke, 1975). 
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3. Creatine Kinase (CK) 
In 1960s, the Creatine Kinase (CK) presented as a better cardiac specific marker to confirm 
acute myocardial damages (Ishikawa, Saffitz, Mealman, Grace, Roberts, 1997). CK, as a 
dimeric molecule, consist of two different subunits known as M and B, which split into three 
distinct isozymes as CK-MB (found predominantly in myocardium), CK-MM (found 
predominantly in skeletal tissue), and CK-BB (found predominantly in the brain tissue) (Adams, 
Abendschein, & Jaffe, 1993). It has been determined that the release of CK-MB is particularly 
obvious following myocardial necrosis (not under ischemic condition)(Wu, 1998), so it was most 
commonly applied in identifying myocardial injury. It can be typically detected in circulation 3–6 
hours following the onset of acute myocardial necrosis, reaches its maximum in 12-24 hours and 
begins to return to normal level within 48-72 hours (Galarraga, 2003). Although sensitivity of CK-
MB is high enough, its extensive tissue distribution will strongly yield poor specificity. In other 
words, CK-MB elevated levels could be observed in various forms of musculoskeletal damage or 
myopathies, diseases of small bowel, uterus, prostate, and diaphragm, renal failure, 
hepatobiliary system disease, non-cardiac surgery, chest trauma, asthma, pulmonary embolism, 
head trauma, hyperventilation, hypothyroidism, during peripartum period and in substance 
abuse like cocaine and alcohol (WHO, 1979; Lee, 1987). Consequently, it has been suggested 
that in order to improve CK-MB specificity, calculating CK-MB relative index as CK-MB/total CK, 
whereas the ratio greater than 2.5 will be associated with myocardial injury (Mair, et al., 1992). 
Thus, the World Health Organization (WHO) confirmed the use of serum AST, LDH, CK, and 
CK-MB levels in presence of clinical and electrocardiographic manifestations to identify acute 
myocardial infarction, in 1979(WHO, 1979). 
4. Myoglobin (MYO) 
Myoglobin (MYO) was introduced as a primary indicator of myocardial damages in 
1978(Kolendorf, Pedersen, Christiansen, & Gad, 2009). It is a globular oxygen-carrying protein 
which found in myocardial tissue and striated skeletal muscle (Ohman, et al., 1990). The first 
report was published in 1975, confirmed the association between elevated serum levels of MYO 
and AMI (Varki, Roby, Watts, & Zatuchni, 1978). Myoglobin can be detected within 1 hour after 
the initiation of myocardial necrosis, reaches its maximum in 4-12 hours and returns to normal 
level within 24-36 hours (Ebashi, 1963).  A high concentration of myoglobin in skeletal muscles 
is the reason why MYO has a poor specificity (Galarraga, 2003;Jaffe, 2012). In other words, 
though myoglobin is one of the earliest serum markers for AMI, there are various medical 
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conditions that could increase myoglobin blood levels in the absence of acute coronary 
occlusion. 
5. Cardiac troponin(cTn), as a biomarker in the current standard of care 
In 1963, it was revealed that a new myofibrillar protein called troponin is integral to muscle 
contraction in skeletal and cardiac muscle and absent from smooth muscle(Takeda, Yamashita, 
Maeda, & Maeda, 2003). 
Biology of the Troponin Complex in Cardiac Myocytes 
Troponin is a complex of three subtypes (Katus, Remppis,  Scheffold, Diederich, & Kuebler, 
1991): Troponin I (Tn I) which binds to actin with Inhibitory role, Troponin T (Tn T) which binds to 
tropomyosin, Troponin C (TnC) which binds to calcium ions and all of them are located on the 
actin filament in sarcomere.  
Sarcomere is the basic contractile unit of muscle cell composed of thin ball shaped filament, 
called actin, and thick filament, called myosin, includes tail, hinge and head as dual- golf club 
shaped. Each muscle fiber or myofibril (a long, cylindrical, multinucleated cell) contains 
hundreds of sarcomeres (Brogan, et al., 1997). 
 
Figure 14. Structure of musculoskeletal contractile cell (Modified from: Marieb,et al.,2010). 
Anatomie et physiologie humaines) 
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Tropomyosin attaches longitudinally to the actin filaments. Each actin molecule has a myosin-
binding site. If calcium ion is unavailable, the binding site of myosin to actin will be blocked by 
tropomyosin-troponin complex. 
 
 
Figure 15. A schematicview:Tropomyosin binds lengthwise along actin filaments and, in striated 
muscle, is associated with a complex of three troponins: troponin I (TnI), troponin C (TnC), and 
troponin T (TnT). In the absence of Ca2+, the tropomyosin-troponin complex blocks the binding 
of myosin to actin. Binding of Ca2+ to TnC shifts the complex, relieving this inhibition and 
allowing contraction to proceed. (Cooper, G. M., & Hausman, R. E. (2009). The cell: a molecular 
approach. Washington, DC: ASM Press; Sunderland, MA: Sinauer Associates, c2009.) 
By binding of calcium ion to the troponin C, tropomyosin moves to lateral side, that causes 
exposed binding side on actin for myosin(dark area), then, results from ATP-hydrolysis, some 
changes occurs in myosin head  that promote to bind myosin head into exposed site(Figures 15 
&16) 
 
Figure 16. Interaction between the actin and myosin filaments ,from:In Fuster, V., In Harrington, 
R. A., In Narula, J., & In Eapen, Z. J. (2017). Hurst's The Heart, 14e. New York, NY: McGraw-
Hill Education LLC 
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It has been assumed that in addition to the structural sources of troponin, there is at least one 
other pool that is called cytosolic pool (Wu, 1998; Thygesen, 2010).The cytosolic or early 
releasable pool for cTnI and cTnT accounts for almost 3.7% (Wu, 1998) and 5% (Thygesen, 
2010) of total released troponin respectively. Consequently, it may justify the long persistence of 
cardiac troponins in blood circulation following an AMI. Besides, cytosolic pool is responsible for 
the biphasic kinetics of troponin as a rapid release of free cytoplasmic troponin and then a 
gradual structural troponin release(Sribhen, Phankingthongkum, & Wannasilp, 2012). 
 
Figure17. Mechanism of release of cardiac troponin after ischemic cardiac injury, available at: 
http://ja.ma/1NKufTm #AMI #heart attack) 
 
Although the biochemical behavior of cTnI is quite clear, that means, cTnT has never been 
detected neither during neonatal development nor in pathologic conditions of all the organs and 
body tissues, except the heart (Tiwari, 2012), the situation of cTnT becomes more complicated.  
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Apparently, the elevated levels of cTnT are detectable in some patients who suffer from 
musculoskeletal disorders or renal failure (Tucker, 1997). Therefore, cTnT could be prone to 
false-positive elevation in the absence of significant coronary artery disease. 
Elevated levels of cTnT and cTnI are detectable within 3-4 h after of the onset of ischemia and 
typically reach its maximum after 12-48 h (Bertinchant, 1996) and stay elevated for 4-10 days 
that refers to a gradual decline in myofibril-bound troponin complex (Jaffe, 2011;Twerenbold, 
2012). Cardiac troponin assays are based on high-affinity antibodies thatare specific for both 
cTnT and cTnI, but because of the uniform amino acid sequences of troponins in both 
myocardial and musculoskeletal origins, measuring cTnC has not been proposed (Tiwari,2012). 
Novel high-sensitivity cardiac troponin assays (hs-cTn), compared to previous generation, in 
order to detect myocardial necrosis with respect to their sensitivity have been developed (Jaffe, 
2011; Twerenbold, Jaffe,Reichlin, Reiter,&Mueller, 2012).Hs-cTn assays provided an opportunity 
to detect cardiac troponin levels which is 10- fold lower in previous assays, hence they are able 
to measure the lowest troponin values in healthy individuals (Apple, & Collinson, 2011). Each 
assay has a unique, incomparable and assigned cut off value that refers to the dissimilarity of 
the antibodies and the different matrix compositions of the assays ( Ferrieres, 1998; Perry, 
1999; Panteghini, 2001). In addition, the various components of circulating troponins are 
distinguished by various assaysin different ways (Venge, Johnston, Lindahl, & James, 2009). 
Furthermore, cardiac troponin can be detected by the new highly sensitive assay in healthy 
individuals that indicates unique variation inside or interindividuals that could refer to a normal 
cardiac cells turnover or an unidentified mechanism (Sandoval, & Apple, 2013; Thygesen, 
Alpert, Jaffe, & White, 2015,). 
28 
 
 
 
Figure 18, Detection range of various cardiac troponin assays (from Hochholzer et al. Am Heart 
J 2010).  
The green line refers to normal turnover of cTn in all human beings. The orange line refers to a 
slight but rapid increase of cTn that reflects either an early-release of cytosolic pool of cardiac 
troponin or myocardial microinfarction.The red line represents a steep rise in cTn levels, 2 -6 
hours after extensive myocardial infarction. In addition to elevated cardiac troponin monitoring, 
hs-cTn assays are designed to detect lower levels of troponin caused by ischemia/micro 
necrosis and the normal turnover as well. While the first generation of cardiac troponin assays 
only detect a significant increase of cardiac troponin. 
Although increased serum troponin level is defined as the value of 99th percentile upper 
reference limit (URL) by including 99% of all troponin values of the given population (Apple, & 
Collinson, 2014), URL values for the same assay could vary significantly in different reference 
groups (Clerico, et al., 2008,Olivieri, 2012).Cardiac troponins assays would be considered as 
highly sensitive tests if: their coefficients of variance are less than 10% at the 99th percentile 
value of the healthy reference population, and the concentrations above the test detection limit 
can be measured in more than 50% healthy population. (Olivieri, 2012). 
Behavior of troponin in the elderly 
Both age and gender significantly have an effecton hs-cTn assays (Missov,& De Marco, 
1999;Olivieri,2012), as it decreases in women and increases with advancing age, this may be 
due to the myocardial ageing, in both sexes, particularlyageing causes a remarkable increase of 
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serum troponin. Consequently, the interpretation of serum troponin in elderly, exceptionally in 
old-old with presence of comorbidities needs further consideration. 
Sensitivity and specificity of troponin 
Although the interpretation of diagnostic tests is a clinical process that have own lexicon with 
regards to its science, the efficiency of a laboratory test is usually presented in terms of 
sensitivity and specificity. 
Both cardiac troponin T and I isoforms are distinctly found in myocardium (Jeremias, 2010),so it 
is a cause of high cardiac specificity for both of them. It is hypothesized that the normal baseline 
troponin values should be 0.1–0.2 ng/L, caused by persistent loss of cardiomyocytes throughout 
life (Panteghini, Pagani, & Bonetti, 1999).Despite the cardiac troponins sensitivity and its 
predictive value have improved over time, its specificity does not change notably over time (Balk, 
2001). 
Sensitivity of cTnT in hospital outpatients varies between 25-65 percent (time zero), increments 
to 59-90 percent at 2 to 6 hours after their admission, and reaches 100 percent within 6 to 12 
hours after admission (Bertinchant,1996;Eggers,, Nordenskjöld, & Lindahl, 2004;Jaffe, Babuin, 
Apple,2006). For cTnI, its sensitivity in time zero is at most 45 percent, increases to 69–82 
percent at 2 to 6 hours after admission, and the same as cTnT, achieves to 100 percent within 6 
to 12 hours after admission (Eggers,  Oldgren, Nordenskjöld, & Lindahl, 2004;Jaffe, Babuin, 
Apple,2006;Twerenbold, Jaffe, Reichlin,  Reiter, & Mueller, 2012).  As a result, the maximum 
sensitivity of cTn assays could be observed longer than 6 hours after myocardial cell death 
occurs (Christenson, 2007; Hammarsten, 2012). Thus, it is recommended to measure cTn blood 
levels at time zero and at least 6-9 hours after patient admission in order to improve the 
accuracy of the diagnosis of myocardial infarction (Koerbin, Tate & Hickman, 2010). 
The positive predictive value, for cTnI, at time zero and 12 hours after admission is estimated to 
be 25% and 89% respectively, whereas for cTnT, is estimated to be 35% and 57% respectively 
(Twerenbold, , Jaffe, Reichlin, Reiter, & Mueller, 2012). The negative predictive value of cTnI at 
time zero and 12 hours after admission is predicted to achieve 85% and 98% respectively, 
whereas for cTnT, it is estimated to be 88% and 99% respectively(Twerenbold, , Jaffe, Reichlin, 
Reiter, & Mueller, 2012). 
The specificity of cTnI and cTnT has been reported to be in the range of 83 - 98 percent and 86–
98 percent respectively (Twerenbold,et al., 2012). 
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Although few studies have been reported that the level of cTn is increased with advancing age 
(Ferri, 2010;Reiter, Reichlin, Twerenbold, & Mueller, 2011;Anderson, 2011), reasons of which 
still remains obscure, even with explanations like presence of more comorbidities or silent heart 
diseases in elderly, and age dependent phenomenon. In other words, the troponin alterations in 
elderly, particularly among the old-old, are not inclusive.Emerging serum cardiac biomarkers is 
summarized in following graphs in the first hours (figure 19) and days (figure 20) after the onset 
of acute myocardial infarction. High-sensitivity assays are capable of detecting cTn in blood 
circulation more accurately even at a concentrations 10 times lower than conventional assays 
(Liu, et al,2017).Therefore, use of high sensitivity assays of troponin could reduce the risk of 
being misdiagnosed with ACS compared with conventional assays. 
 
Figure 19.Time courses (hours) for elevation of various biomarkers after the onset of symptoms 
of AMI.( Source : Michael L. Bishop, et al. Clinical chemistry, 6th edition, 2010, chapter 25, 
cardiac function, page 551, ISBN 978-0-7817-9045-1) 
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Figure 20.Time courses (days) for elevation of various biomarkers after the onset of symptoms 
of AMI. Reprinted from:Goodier, J. (2009). Lippincott Williams & Wilkins anesthesiology, creatine 
kinase-MB to troponin: the adoption of a new standard.  
As it is explained, reference values for cardiac troponin encompass the values of 99% of a 
healthy population, the results vary between different laboratories, so at present, there is still no 
certain standard consensus on which cut-off point value should be used (Jaffe,2000).The 
baseline of troponin level has been suggested as 0-0.4 ng/ml (negative), 0.05-0.49 ng/ml and 
≥0.05 ng/ml for intermediated risk and strong risk of acute myocardial infarction respectively 
(Lippi,  Sanchis-Gomar, & Cervellin,2016). 
In conclusion, to this date, among available cardiac biomarkers, cardiac troponin is the 
biomarker of choice to detect acute coronary events (Sanchis-Gomar, Perez-Quilis, Leischik, & 
Lucia, 2016). 
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Causes of increased cardiac troponin values 
Although cardiovascular disease (CVD) has been defined as a group of diseases that involve 
both the heart and blood vessels(Fitchett, et al.,2011),at some point, there is an ambiguity in 
defining its related-conditions such as coronary heart disease (CHD), coronary artery disease 
(CAD), and acute coronary syndrome (ACS).  
CHD refers to heart diseases such as angina pectoris, MI and silent myocardial ischemia, but 
CAD typically apply to indicate pathologic changes in the coronary arteries that usually caused 
by atherosclerosis. In other words, CAD is a condition which characterized by atherosclerosis in 
coronary arteries, could refer to pathologic process and can remain symptomless (Lippi, & 
Cervellin, 2016). Instead, ACS nearly always becomes symptomatic and it is a life threatening 
condition, irrespective of the presence of CAD (Roffi,2015). 
There are different approaches to classify the clinical conditions other than myocardial infarction 
that cause cardiac troponin to rise. One of the more detailed classifications related to cTn 
increase is presented as (Apple, & Collinson, 2014): 
1. Troponin leak primary to myocardial ischemic injury: Plaque rupture, Intraluminal 
coronary artery thrombus formation 
2. Troponin leak secondary to myocardial oxygen supply-demand imbalance: tachy-/brady-
arrhythmias, aortic dissection or severe aortic valve disease, hypertrophic 
cardiomyopathy, shock (cardiogenic, hypovolemia, or septic), severe respiratory failure, 
severe anemia, hypertension with or without left ventricular hypertrophy, coronary 
spasm, coronary embolism or vasculitis, and coronary endothelial dysfunction without 
significant CAD 
3. Troponin leak not associated with myocardial ischemia: cardiac (contusion, surgery, 
ablation, pacing, or defibrillator), shocks, rhabdomyolysis with cardiac involvement, 
myocarditis, cardiotoxic agents (e.g. Anthracyclines, Herceptin) 
4. Multifactorial or undefined myocardial insults: heart failure, stress (Takotsubo) 
cardiomyopathy, severe pulmonary embolism or pulmonary hypertension, sepsis and 
critically ill patients, renal failure, severe acute neurological diseases (e.g. stroke, 
subarachnoid hemorrhage), Infiltrative diseases (e.g. amyloidosis, sarcoidosis), 
strenuous exercise 
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Consequently, detection of elevated serum concentrations of cardiac troponin (>99th percentile 
URL) in the presence or absence of ischemic heart disease symptoms, or other diagnoses 
associated with myocardial damage have to be ruled out. 
Acute Coronary Syndromes (ACSs) 
ACS - as a subset of CHD addresses a range of conditions that are compatible with unstable 
angina (UA), non ST-segment elevation myocardial infarction (NSTEMI), and ST-segment 
elevation myocardial infarction (STEMI) - causes a decrease levels in coronary artery blood flow 
(Bertrand, 2002). 
As discussed above, the underlying etiology of ACSs is the atherosclerosis, which is 
characteristically composed of a vulnerable plaque with a thin layer of fiber and a large lipid 
core. Sooner or later, this plaque tears, causes platelet accumulation and activation, which lead 
to coronary thrombus formation, narrows the coronary arteries and ultimately reduces the flow of 
oxygen-rich blood to the section of heart muscle that is fed by the coronary artery. 
It can be difficult to distinguish UA from NSTEMI (Mega, 2005). UA is defined as myocardial 
ischemia that occurs at rest or even with slight physical exertion without any presence of 
cardiomyocytes necrosis, so that is distinguishable from NSTEMI by the pain frequency-severity-
duration to cause myocardial necrosis (Cannon, 1997). ECG findings associated with UA can be 
found in 30-50 percent of the patients, including normal morphology, ST-segment depression, T-
wave inversion, or due to a combination of all these factors, may vary depending upon the 
severity of clinical presentations (Ottani, 1999, Antman, 2004). Although small amounts of cTn 
could be traced in the serum of patients suffering from UA, it has not been shown any prognostic 
value in predicting future coronary events (McCarthy,, Wong, & Selker, 1990). 
 
Figure 21. ECG of unstable angina, (available at: http://nstemi.org/unstable-angina/, accessed: 
July 5, 2017) 
STEMI is typically the result of an acute and sudden complete interruption of blood flow to part 
of the myocardium which could be displayed as an unusual pattern by ECG with ST-segment 
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elevation, whereas NSTEMI mostly results from a partial occlusion which develops to become 
total blockage of coronary artery as well, but does not exhibit ST segment elevations in 
ECG(Figure 22). STEMI is the most severe type of ACS with the highest mortality rates 
(Goodacre, 2002). 
Figure 22. Acute Coronary Syndrome, unstable angina and non-ST elevation myocardial 
infarctionModified from: Ange, R. A., & Hillis, L. D. (2015). Acute Coronary Syndrome. 
Goldman's Cecil Medicine. Acute Coronary Syndrome, unstable angina and non-ST elevation 
myocardial infarction, Goldman-Cecil Medicine, pages 432-440 
 
Main clinical presentations 
A typical symptoms of ACS include chest pain (most common), referred pain (arm, the jaw, the 
neck, the back, or the abdomen), nausea, vomiting, dyspnea (may be as a sudden onset), 
diaphoresis, light-headedness (Alexander, 2007). Referred or radiating pain to the shoulder, left 
arm, or both arms may increase the probability of ACS (Avezum, 2005). 
35 
 
 
 
Figure 23. Chest Pain and Acute Coronary Syndrome,Reprinted 
from:https://jamanetwork.com/journals/jama/fullarticle/2468893 
 
Diagnostic evaluation 
The main step for assessment of a patient with ACS is to distinguish the probability of coronary-
artery disease as causing any symptoms. The American College of Cardiology/American Heart 
Association (ACC/AHA) proposed guidelines include, among the factors associated with the high 
probability of ACS, prior history of angina, AMI or CHF, History of established CAD by 
angiography, new ECG changes, and elevated cardiac biomarkers (Jaffe, et al.,2000). 
Identification of ACS in older patients  
Seniors often experience a different range of symptoms, so the diagnosis of ACS among them is 
challenging. Although chest pain is still the most frequent symptom in older patients, autonomic 
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symptoms such as syncope, malaise and confusion can be the only presenting symptom of ACS 
among elderly (Elbarouni, et al.2009). Not only electrocardiogram includes the relatively high 
prevalence of disturbances such as left bundle brunch block or left ventricular hypertrophy, but 
also increased troponin levels may be affected by comorbidities such as diabetes or renal failure 
(Twerenbold, Jaffe, Reichlin, Reiter, & Mueller, 2012). Additionally,more than two out of five  
ACS patients are aged 85 years or over do not present diagnostic ECG abnormalities compared 
with a quarter of those under 65 years (Veerasamy, et al.,2015).Moreover, in elderly, NSTE-ACS 
instead of STEMI is frequently observed (Alpert, Thygesen, Antman, & Bassand, 2001; Storrow, 
Lardaro, Alexander, & Apple, 2013). 
Consequently, this significant age -related characteristics of ACS in elderly patients could lead to 
uncertainty in initial diagnosis or misdiagnosed on admission and treatment in a timely and 
accurate fashion. 
Acute Myocardial Infarction (AMI) 
AMI definition refers to cardiomyocytes necrosis from a sudden and a prolonged ischemia during 
the course of events in acute coronary syndromes in subsequent development of 
atherosclerosis (Higgins, & Higgins, 2003).  Advanced age as an established risk factor is one of 
the leading cause of formation and progression of atherosclerotic plaques. Currently, due to 
extensive use of cTn, AMI definition has been turned from a clinical diagnosis that was made on 
the basis of ECG findings and biomarkers blood levels to a laboratory measurement of cTn 
which is supported by clinical and ECG findings (Nguyen Dang, Karlsson, & Herlitz, 2016).  
Acute myocardial damages lead to a biphasic rise of serum troponin levels that resulted from the 
primary release of cytosolic pools and then from myofibrillar structural sources (141,194). Detection 
of the increase and /or decrease of cardiac troponin is the principle of consensus in new 
definition of MI, along with one of the myocardial ischemic symptoms, ECG disturbances and 
cardiovascular diagnostic imaging tests that appear a new regional loss of viable myocardium, 
and recognition of occlusive intracoronary thrombus at autopsy(Apple, & Collinson, 2014). 
AMI in the elderly 
In older patients with AMI, not only the presence of atypical symptoms is more frequent, but also 
the elderly patients compared to the younger patients are exposed to a higher mortality rate 
(Rittger, 2011, Banach,2005). Furthermore, in elderly patients with AMI, both perception and 
location of ischemic pain maybe changed (Yarzebski, Goldberg, Gore, & Alpert, 1994). They 
37 
 
 
may describe their complaints as autonomic symptoms such as dyspnea, syncope, shoulder or 
back pain, weakness, fatigue (in women), acute confusion or altered mental status (particularly if 
the patients aged over 85 years(Roberts, & Kleiman,1994),epigastric discomfort and even could 
be described by concurrent disorders. In addition, pre-hospital delay in the elderly patients with 
AMI has been reported frequently, that could be related to atypical chest pain, diminished chest 
discomforts, cognitive impairment, comorbidities, or social restrictions (Han, et al., 2007). 
 
Figure 24.  Presentation of AMI according to patient age.Precordial pain is decreased with 
advancing age. Reprinted from: Bayer, Chadha,Farag, & Pathy, 1986) 
 
Scope of the Problems 
As aforementioned, there is often an interaction between the physiological processes of aging 
and age-related pathological processes in the cardiovascular system. Thus, in age-related 
cardiovascular diseases, aging may alter the clinical manifestations, responses to treatment, and 
outcomes of ACS or AMI. As a result, clinical standards have to be in accordance with age, if 
not, they may not be applicable to different age groups. Older patients with acute coronary 
events may present with atypical symptoms, so elderly patients could benefit more from 
laboratory methods, like hs-cTn, than younger patients. On the other hand, it has recently been 
reported a great possibility of false positives for hs-cTnT assay in elderly patients with AMI 
(Ferri, 2010). The major conflict in elderly patients, particularly those 80 years of age and older is 
the lack of reliability of diagnostic characteristics such as chest pain, electrocardiography, and 
interpretation of biomarkers, in order to exclude AMI (Barron, et al., 1998). Further, positive 
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predictive value of chest discomfort in order to diagnose AMI in elderly patients is decreased 
(Morrow, Antman, & Tanasijevic, 2001). It can be exemplified by diabetes mellitus which may not 
have chest pain during AMI (Ahmed, et al., 2013). 
On the other hand, the numbers of participants over the age of 80 that have been recruited in 
the most elderly acute coronary syndrome trials are restricted; hence, limited resources are 
available for evidence-based management regarding this rapidly growing subset of ACS 
patients. Moreover, the presence of particular multiple chronic conditions and comorbidities in 
elderly patients may result in ''atypical'' or ‘’asymptomatic’’ presentations(Elbarouni, et al., 2009), 
it could preclude optimal evaluation of older adults with ACS.  
AlthoughcTn has been well-known as the best biomarker to detect myocardial necrosis, there is 
little available data about cTn behaviors in elderly patients and even fewer in very old patients 
with AMI (Inbar, et al., 2009). Consequently, very old patients evaluated for excluding AMI are 
frequently prone to misdiagnosis (Borna, Frostred, & Ekelund, 2016). 
Ithas been proven that that the lack of clinical standardization to determine the causes of cTn 
elevation in the elderly patients with AMI could lead to over diagnosis and misdiagnosis as well 
(Zhang, et al., 2016). 
In the most recent clinical studies, despite including the geriatric patients in order to determine 
the relationship between cardiac troponin value and AMI, they are mostly grouped together in a 
single group without regrouping by age range, so the characteristics of cTn assays in AMI/ACS, 
particularly in very old patients with or without comorbidities have not been clarified precisely.  
The influence of ageing and presence of comorbidities in diagnostic criteria for ACS or AMI is 
under question. Even though based on the 99th percentile of a healthy population, the cutoff 
value of hs-cTnT  is less than 0.014 ng/mL (Noeller,et al,2003), its proper cutoff value in an 
elderly - particularly very elderly- population suffering from comorbidities with acute coronary 
syndrome is considered as a challenging diagnostic scenario. Few studies have suggested that 
the diagnostic value of the hs-cTnT levels might not be appropriate or might be different in 
elderly patients with comorbidities (Ferri, 2010; Zeller, et al, 2015; Mueller-Hennessen, et al., 
2016).In contrast to these studies, some studies have suggested that cTn levels increase with 
age(Ferri, 2010; Reiter, Reichlin, Twerenbold, & Mueller, 2011; Anderson, 2011). 
Therefore, an appropriate interpretation of an elevated hs-cTnT in elderly patients with 
comorbidities could have a considerable influence on ACS risk stratification. 
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Moreover, the hs-cTn assays have been shown to be associated with higher frequency of false-
positive for AMI in very old patients (Ferri, 2010). It is reasonable to make an executive clinical 
decision in elderly patients with suspected acute coronary necrosis, age-based troponin values 
in the presence or absence of comorbidities should be considered. 
In summary, the value of cTn in the elderly population is really not known and the present 
literature statement that it is increasing with age lead to its misuse and misinterpretation in the 
diagnosis of AMI. 
Research question 
In order to refine the risk stratification for AMI in elderly patients, particularly in very old patients, 
with or without comorbidities, the following questions have been raised: 
➢ Could advancing age have an effect on the value of high-sensitive cardiac troponin T (hs-
cTnT) in elderly patients with one or more comorbidity symptoms? 
➢ Is there any relationship between cardiac troponin values with the advancing of age? 
➢ What is the relationship between cardiac troponin values with comorbidities? 
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Literature review 
An extensive search of original articles and reviews was done from 1990 to 2016. We used 
EMBASE and PubMed in addition to Scopus.  
The key word “Acute coronary events”, with a combination of subtitles such as: [Acute 
myocardial infarction] OR [AMI] OR [ACS] OR [Myocardial Injury] OR [Myocardial Necrosis] AND 
[cardiac biomarkers] OR [Cardiac troponin] OR [cTn I] OR [cTn T] OR [Troponin assays] OR [hs-
cTnT] OR [hs-cTnI] OR [99th percentile decision level for troponin] OR [Troponin assay 
impression] AND [aged people]  OR [the population aged 65 years and older] OR [very old 
patients] OR [Older Adults] OR [In elderly Patients] OR [geriatric] OR [geriatric patients] OR 
[gerontology]   
This research identified 231 publications that were analyzed first for the relevance of the title and 
abstract, and then reading the entire article. We only retained articles published in English or 
French between 1990 and August 2017, and reported data on AMI for a population aged 65 
years and over. This study aimed to answer to questions referring to the relationship between 
age, comorbidities and acute coronary syndrome in aged patients, with respect to changes in 
the level of high-sensitive cardiac troponin T.   
The literature review of the above-mentioned questions provided poor outcome, mainly due to 
inadequate consensus on the definition of elderly and very elderly in different studies. 
Consequently, the lack of studies on elderly patients, particularly very elderly confined our 
reviews ultimately to 20 articles. 
The majority of these articles aimed to assess the diagnostic performance of high-sensitive 
cardiac troponin T in response to acute coronary events (Borna, 2016, Zhang and Hennessen 
2015, Rains, 2014, Gore, 2013, Olivieri, Covino and Normann, 2012, Bahrmann, 2011, Reiter, 
2010). 
Although all mentioned studies utilized different methodology, their research produced the same 
results. Some studies revealed that having the elevated levels of hs-cTnT is a common finding in 
elderly patients without acute coronary heart diseases (Borna, 2016, Zhang, 2015, Reiter, 2010). 
In other words, they expressed doubts about the value of hs-cTnT in geriatric patients with 
suspected acute coronary events as it is already increased with advancing age. One study 
minimized the diagnostic role of hs-cTnT in very elderly patients (Covino, 2012). 
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Some researchers justified their result with possible influence of concomitant diseases on 
elevated troponin levels (Zhang, 2015, Normann, 2010). The main conclusions of the above 
studies were identical about the influence of age on troponin levels in elderly. In addition, the 
authors criticized the diagnostic characteristics of the troponin assays in the elderly. They 
proposed that an age-adjusted hs-cTnT cut-off value is necessary in elderly. One study 
concluded (Carro and Kaski, 2011), controversially that interpreting an elevated troponin in 
elderly as a myocardial necrosis may lead to over-diagnosis of acute myocardial infarction. 
Other related studies in our literature review aimed to evaluate the prevalence of hs-cTn 
elevation in elderly and its association with comorbidities (Zeller and Webb, 2014, Eggers, 2008, 
Fromm, 2007, Myint, 2006 and Wallace, 2005). Although some of these studies have considered 
the association of increased hs-cTnI and concomitant diseases (Zeller, 2014 and Eggers, 2008), 
they have a common conclusion that is a positive association of elevated cardiac troponin in the 
presence of comorbidities among patients with acute cardiac coronary events. They concluded 
that the value of cardiac troponin depends on age, comorbidities, black race (Wallace, 2005), 
sex (Zeller, 2014) as well as acute coronary events. 
The studies conducted by Reins and Myint (2014), and two other articles (Zaman, 2010 and 
Zethelius, 2005) aimed to investigate the prognostic role of elevated cardiac troponin and 
mortality. They found that the mortality rate was increased in elderly patients with acute coronary 
events and higher elevated troponin level. 
In 2017, a study on impact of ageing on hs-cTnT in patients suspected of AMI (Taro Ichise et al, 
2017) concluded that an accurate assessment of hs-cTnT in the elderly is necessary, particularly 
in presence of renal dysfunction. 
Literature review conclusion 
Despite the specificity of cardiac troponins (cTnT or cTnI) to detect acute coronary events, their 
applications in the elderly, particularly in very elderly patients, where the patient's medical history 
tend to be less reliable, require a proper interpretation in addition to consider the related clinical 
conditions that cause elevated troponin levels such as comorbidities. Furthermore, studies 
remain inconclusive to clarify whether elevated cardiac troponin levels are due to higher 
comorbidity, undiagnosed /silent ischemic heart disease, or an age-related phenomenon in 
elderly and very elderly patients. Moreover, the level of diagnostic value of cTn, among very old 
patients with or without comorbidities is still controversial. 
42 
 
 
Objectives 
It is imperative to determine the predictive value of cardiac troponin in the elderly and very 
elderly patients to more accurately diagnose acute coronary events, particularly in those who 
have concomitant diseases. 
The principal objective 
The main objective of the present study is to determine the effect of age on the value of hs-cTnT 
in older adults with one or more comorbidities in order to predict the probability of occurrence of 
an acute coronary event. In other words, it is aimed to determine the level of hs-cTnT, which 
may change with different age and gender in elderly and very elderly patients, considering the 
presenceof comorbidities such as chronic heart failure, respiratory disease, renal or hepatic 
insufficiency, cancer and diabetes. Consequently, in addition to the significant variation in hs-
cTnT that may influence mortality rate in the elderly patients, it should be taken into 
consideration according to the presence of or absence of concomitant diseases in order to 
manage the very old patients with ACS more accurately. 
Hypotheses  
Based on literature review, the role of hs-cTn in the detection of ACS/AMI in elderly patients has 
been investigated in a few research studies without a definitive conclusion. Moreover, there has 
been no extensive research to indicate the level of hs-cTnT in the very elderly patients with 
comorbidity. The lack of in depth study of the above issue is the motive of this study.  
We suppose that due to pathophysiological changes in the very elderly who have no clinical 
signs of cardiac necrosis, there is an age-related increase of serum troponin levels. 
Consequently, it is hypothesized that hs-cTn should be adapted for different age groups in very 
elderly patients with the presence or absence of comorbidities in order to improve the diagnostic 
accuracy of acute coronary events in geriatric patients. 
It also could be hypothesized that the level of hs-cTnT increases with the presence of one or 
more comorbidities. 
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Methodology 
Two local hospitals of Sherbrooke University, CHUS - Fleurimont and CHUS - Hôtel-Dieu have 
participated in this retrospective observational cohort study. The medical record data of 
participants in the present study have been evaluated from 2012 to 2016. 
Targeted population 
Participants of the study were all patients, aged 65 years and over,  admitted at the CHUS - 
Fleurimont and Hôtel-Dieu sites for suspected ACS between the period from January 2012 to 
December 2016 in and for whom serial analysis of hs-cTnT levels have been performed . In all, 
6,977 elderly patient records have been identified. 
 
Exclusion criteria 
➢ The subjects with myocardial infarction over previous 365 days. 
➢ Postoperative AMI 
➢ Missing data in medical record 
➢ All geriatric patients who experienced cardiac arrest 
Variables 
Two types of variables were included in present study: 
1. The main variable(dependent):  
➢ Hs-cTnT values 
➢ List of comorbidities: diabetes, chronic heart failure, coronary artery disease, 
respiratory disease (e.g. COPD), renal or hepatic insufficiency, cancers, 
hypertension, neurocognitive disorders, hypothyroidism, anemia, cardiomyopathy, 
pulmonary hypertension, pulmonary embolism, pneumonia, stroke, 
atherosclerotic vascular disease, subarachnoid hemorrhage, cardiovascular 
disease  
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2. demographic variables(independent): age and sex 
Ethical considerations 
This is a retrospective cohort medical records study that the data was collected previously. 
Therefore, there is no recruitment process. The research ethic committee of CIUSSS de l’Estrie-
CHUS. Access of patient records was allowedonly as fully anonymized medical records. In other 
words, there is no access to nominal information, so it is impossible to identify participants. In 
addition, to ensure the confidentiality, the obtained data were stored in a new file and in order to 
enhance the security of data, the created file was encrypted in researcher's computer. 
Furthermore, the results of the present study will be published in aggregate and anonymous 
form. No serious risks were provided by the present study, for the participants (here the 
anonymous medical records) or the society, according to the nature of this study. 
Statistical approach 
Continuous variables were expressed as means +/- standard deviation (SD).Categorical 
variables were expressed as absolute values and percentages of the total.Independent t-Tests 
(to compare the troponin value between different age groups). Chi-square tests or Pearson χ2 
tests (to evaluate the difference in the prevalence of comorbidities according to the level of 
troponin). Multivariate logistic regression (to quantify the risk of having a high level of troponin 
associated with age and comorbidities). Data were analyzed using SPSS (v24; IBM, USA). The 
statistical significance level of study was set at a P < 0.05. 
 
Anticipated result 
It is predicted:  
➢ To confirm a significant differences of hs-cTnT values by sex and age groups 
➢ To determine an elevated of hs-cTnT with confirmed comorbidity  
Data sources: We used the administrative database (InfoCentre) that records patients admitted 
to the CIUSSS- Estrie CHUS and includes all elderly patients, to identify patients with 
comorbidities and at least one hs-cTnT level analyzed data.We reviewed the records of all 
patients to evaluate demographic and clinical characteristics as age, sex, and pre- existing 
comorbidities. 
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Outcomes: A total of 6977 medical records of patients aged ≥ 65 years were included in the 
study data base. After excluding all medical records with the previous or post-operative AMI and 
any experienced cardiac arrest, medical records of 6822 elderly patients were grouped into 
three age groups: patients aged 65 to 74 years (young-old), patients aged 75 to 84 years(old) 
and patients ≥85 years old(old-old). 
Biomarker assay: Patients were presented in this study had serial measurement of hs-cTnT.  
The first blood sample for of hs-cTnT measurement that was collected at time of admission to 
the hospital or emergency department was considered. In our hospitals, hs-cTnT is measured 
using the elecrochemiluminescence immunoassays with Roche Elecsys analyzers (Troponin T 
Stat, Roche Diagnostics, F. Hoffmann-La Roche Ltd, Basel, Switzerland), with a limit of 
detection of 3 ng/L. 
Results:  
Three thousand four hundred and thirty-nine male patients (50, 4%) and three thousand three 
hundred and eighty-three female patients (49. 6%) were included in this study. Table I shows 
demographic and clinical characteristics of the study cohorts. Seventeen significant 
comorbidities were identified in our sample and consist of anemia, Cerebrovascular 
accident(CVA), malignancy, cardiomyopathy, coronaropathy, pulmonary embolism(PE), 
subarachnoid hemorrhage(SAH), diabetes, Arterial hypertension(AHTN), pulmonary 
hypertension(PHTN), hypothyroidism, renal insufficiency(RI), atherosclerosis vascular 
disease(AVSD), chronic obstructive pulmonary disease(COPD), obesity, pneumonia, and 
neurocognitive disorder(NCD). The maximum age of 104 was found in this study that included 
one man and one women. The aged man was suffering from four comorbidities (anemia, SAH, 
HTN and pneumonia) with hs- cTnT value of 42 ng/l , while the aged women was suffering from 
seven comorbidities (CVA , HTN , RI , NCD, hypothyroidism, coronaropathy, and pneumonia) 
with hs-cTnT values of  30 ng/l. We also identified that the arterial hypertension was the most 
frequent comorbidity while the cardiomyopathy that was the least frequent condition in our 
sample. 
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Table I. Demographic and clinical characteristics of the study cohort 
The variables 65-74 years old (n = 
2555) 
75-84 years old (n 
= 2490) 
≥85 years old 
   (n =1777) 
All patients 
     (N = 6822) 
Age( x̅ ± SD) 69 ± 2.83             79 ± 2.88                89 ± 3.62                 78.3 ± 8.3            
Sex (N. %) 
Men 
Women 
 
1469. 57 
1059.43 
 
1294.52 
1196.48 
 
649.36 
1128.64 
 
3439.50.4 
3383.49.6 
Hs-cTnT ng/l 
( x̅ ±SD) 
 
Men 
Women 
 
 
93±312.15 
 
104±353.0 
78±242.34 
 
 
 
 
 
 
283. 48 
349.52 
 
 
 
169.39 
263.61 
 
 
 
 
313. 41 
442.59 
 
 
 
294.43 
397.56 
 
77±234.46 
 
80±183.73 
74±279.19 
 
 
 
 
 
 
228.52 
207.48 
 
 
 
188.48 
204.52 
 
 
 
 
355.48 
392.52 
 
 
 
425.46 
491.54 
 
63±162.73 
 
70±125.32 
59±180.71 
 
 
 
 
 
 
132.61 
83.49 
 
 
 
149.58 
78.42 
 
 
 
 
 
354.67 
174.33 
 
 
 
493.61 
314.39 
 
79±252.14 
 
89±264.64 
70±238.45 
 
 
 
 
 
 
643.48 
684.52 
 
 
 
506.48 
545.52 
 
 
 
 
 
1022.51 
1008.49 
 
 
 
1212.51 
1202.49  
Comorbidities 
(%. N) 
 
Quartile I 
(19.4. 1291) 
Men 
Women 
 
Quartile II  
(15.4. 1048) 
Men 
Women 
 
Quartile III  
(19.8. 2030) 
Men 
Women 
 
Quartile IV  
(35.4. 2414) 
Men 
Women 
 
Hs-cTnT (High-sensitivity cardiac Troponin T), ng/l= nanogram/liter, Quartiles (I=1-2 
comorbidities, II=3 comorbidities, III=4-5 comorbidities, IV= ≥ 6 comorbidities)                        
Patients were divided into 3 categories according to the tertile of hs-cTnT concentration with 
tertile 1 (0-14 ng/L = low level: normal, according to the manufacturer instructions), tertile 2 (15-
31 ng/L=moderate level) and tertile 3 (≥32 ng/L=high level). Furthermore, patients were grouped 
into four categories according to the presence of comorbidity with: quartile 1 (one or two 
comorbidity), quartile 2 (three comorbidities), quartile 3 (four to five comorbidities) and quartile 4 
(≥ 6 comorbidities). 
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Two thousand four hundred and fourteen patients had six or more comorbidities (35. 4%).The 
average age and hs-cTnT level of our sample was 78.3 years, and 79.9 ng/L respectively. Table 
II shows general characteristics of the study cohorts according to the defined variables. The 
standard deviation of total and all quartile from the mean of troponin level was considered 
significant.  
Table II. General distribution of hs-cTnT of the study cohorts, according to sex. 
The variables Total 
(X̄ ± SD) 
     Men 
  (X̄ ±SD) 
Women 
(X̄ ±SD) 
P-value 
HS-cTnT, ng/l 
(X̄ ±SD)   
Q I 79 ± 324.68  93± 416.20 65 ± 181.78 p>0.05 
Q II 81 ± 290.86 89±263.39 71±317,80 p>0.05 
Q III 89±264,02 97±242,62 81±283,43 p>0.05 
Q IV 71±161,85 66±203,50 76±119,84 p>0.05 
Quartiles (I=1-2 comorbidities, II=3 comorbidities, III=4-5 comorbidities, IV= ≥ 6 comorbidities), 
Hs-cTnT (High-sensitivity cardiac Troponin T), SD (standard deviation) 
 
In both sexes, the troponin value across all age groups, with any types of comorbid disease, was 
remarkably high (> 32 ng/l). In men, the hs-cTnT value was decreased for both old group and 
old-old group compared to the young-old group, that was statistically significant (p <0.05) . 
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Figure 25.High-sensitive cardiac troponin T level in all male age groups (* means statistically 
significant, p<0.05) 
 
Although the hs-cTnT values in women had shown to have decreased, the difference was 
statistically not significant in all age groups. 
 
Figure 26.High-sensitive cardiac troponin T level in all female age groups  
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The distribution of hs-cTnT with regards to age and comorbidities is shown in table III. 
Obviously, the troponin level was decreasing according to age for each comorbidity, although 
not statistically significant.  
Table III. General distribution of hs-cTnT of the study cohorts, according to age and comorbidity. 
The quantiles 65-74 years 
old (X̄ ±SD) 
75-84 years old 
(X̄±SD) 
≥85 years 
old (X̄±SD) 
P-value 
Ι (1-2 comorbidities) 93 ± 423.99 70 ± 190.18 53 ± 102.50 p>0.05 
II (3 comorbidities) 92±272,50 80±368,09 59±127,67 p>0.05 
III (4-5 comorbidities) 103±314.94 91±266,42 67±158,85 p>0.05 
IV (≥ 6 comorbidities) 82 ± 171.87 67±127,75 64±185,59 p>0.05 
Furthermore, the presence of hypertension and renal insufficiency made an exception that it was 
statistically significant as shown: The hs-cTnT level decreased in the presence of arterial 
hypertension in both groups of old and old-old, whereas, the troponin level decreased only in 
group of old-old in the presence of renal insufficiency (p<0.05)       (Fig.14). The highest troponin 
levels were discovered in patients with renal insufficiency; in contrast, the lowest troponin levels 
belonged to patients with neurocognitive disorders. 
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Figure 27.Troponin value of age groups in men with different commodities. CVA= 
cerebrovascular accident, PE=pulmonary embolism, SAH= subarachnoid hemorrhage, 
HTN=hypertension, PHTN = pulmonary hypertension, RI=renal insufficiency, AVD= 
atherosclerotic vascular disease, COPD=chronic obstructive pulmonary disease, 
AND=neurocognitive disorder. * Statistically significant, Chi-square tests used to compare 
between troponin levels and age sub-groups and comorbidities. 
Noticeably, in women the highest troponin levels were discovered in patients with 
cardiomyopathy, that were strongly elevated, in contrast, the lowest troponin levels were 
detected in patients with neurocognitive disorders.  
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Fig 28. Troponin value of age groups in women with different commodities. 
CVA= cerebrovascular accident, PE=pulmonary embolism, SAH= subarachnoid hemorrhage, 
HTN=hypertension, PHTN = pulmonary hypertension, RI=renal insufficiency, AVD= 
atherosclerotic vascular disease, COPD=chronic obstructive pulmonary disease, 
AND=neurocognitive disorder. Chi-square tests used to compare between troponin levels and 
age sub-groups and comorbidities.  
 
Clearly, the troponin levels were decreased as a function of age among all comorbid conditions 
(p > 0.05). In fact, among all pre-existing medical conditions, the highest levels of troponin were 
observed in the young-old group (65 to 74 years old). Cancer and pulmonary embolism, were 
two exceptions, whereas, troponin values were more elevated in both old groups. Indeed, the 
young old-group (65-74 years old), among all comorbidities, were most affected by elevated 
troponin levels, except for two comorbidities: cardiomyopathy and pulmonary hypertension, 
where troponin values were more elevated in old group (patients aged ≥ 75 and 84 years). After 
calculating the average amount of hs-cTnT levels for each age group, it was discovered that the 
patients in the younger cohorts had higher elevated rates of hs-cTnT values. In men, troponin 
values across all quartiles of comorbidities were decreased as a function of age (Fig. 16). In 
other words, the highest values of troponin were detected in young-old group, whereas, the 
lowest values were shown in old-old group. 
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Fig 29. Troponin value of age groups in men with different comorbidities. Quartiles (I=1-2 
comorbidities, II=3 comorbidities, III=4-5 comorbidities, IV= ≥ 6 comorbidities). 
 
Although in women, troponin values across all quartile of comorbidities were decreased with 
advancing age (p>0.05), (Fig.17), in the second quartile group (Quartile II), the highest troponin 
levels were shown in old group (patients aged 75-84 years). 
 
Fig 30. Troponin value of age groups in women with different comorbidities. Quartiles (I=1-2 
comorbidities, II=3 comorbidities, III=4-5 comorbidities, IV= ≥ 6 comorbidities). 
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Although in both sexes hs-cTnT values were decreased with advancing age in all quartiles, it did 
not come out statistically significant (p>0.05). 
Odd Ratio 
Obviously, the probability of having raised levels of troponin was increased with all types of 
comorbidities. But contrary to our first data analysis as explained above, when we applied odds 
ratios instead, the Hs-cTnT levels increased with advancing age.In order to found the reason for 
observed inconsistency, a further analysis of data was conducted. 
In our pooled analysis of patients’ medical records, plasma levels of Hs-cTnT had a non-
parametric distribution. In other words, the level of Hs-cTnT was extremely the level above the 
reference range, that means a lot of patients had raised Hs-cTnT level more than 33 ng/l 
whereas the standard deviation that was of greater magnitude than its mean.  
Therefore, we applied the median to present Hs-cTnTvalues (interquartile range). 
Table IV-the median distribution of Hs-cTnT of the study cohorts, according to age and 
comorbidity 
 
 Male Female 
 Median [Q1 ; Q3] Median [Q1 ; Q3] 
65-74 years 24,0 [13.0; 57.2] 19,0 [9.0 ; 45,2] 
75-84 years  33,0 [19.0; 63,0] 24,0 [14.0 ; 48,0] 
85+ years  39,0 [25.0; 67,2] 31,0 [20.0 ; 52,0] 
Q1: 25 percentile; Q3: 75 percentiles 
Apart from the mean, even after the application of the median, it was shown that the Hs-cTnT 
levels increased in the presence of comorbidity in both groups of men (Figure 29) and women 
(Figure 30). 
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Figure 31. Troponin value of age groups in men with different commodities. CVA= 
cerebrovascular accident, PE=pulmonary embolism, SAH= subarachnoid hemorrhage, 
HTN=hypertension, PHTN = pulmonary hypertension, RI=renal insufficiency, AVSD= 
atherosclerotic vascular disease, COPD=chronic obstructive pulmonary disease, 
AND=neurocognitive disorder.  
 
 
Figure 32. Troponin value of age groups in women with different commodities.CVA= 
cerebrovascular accident, PE=pulmonary embolism, SAH= subarachnoid hemorrhage, 
HTN=hypertension, PHTN = pulmonary hypertension, RI=renal insufficiency, AVSD= 
atherosclerotic vascular disease, COPD=chronic obstructive pulmonary disease, 
AND=neurocognitive disorder.  
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The measure of effect, here age, is expressed as odds ratio which is not influenced by troponin 
levels. 
Apparently, with each increase in the number of comorbidity in men’s group, the risk of having a 
moderate and high level of hs-cTnT has shown to have increased by 1.38 [1.3; 1.44] and 1.22 
[1.16; 1.28].In groups of men, the odd ratio of high dose and moderate dose of troponin was 
discovered highest in old-old and old group respectively. In other words, the odds ratio for 
elevated troponin level and age was more than 1 in both women and men. In fact, within each of 
the troponin tertiles, index levels on age quartiles were significantly increased with the increase 
of age, and vice versa.  
Table V. Odd Ratio in men, by considering age groups and comorbidities 
Male              
Reference category:  
Hs-cTnT (0-14ng/l) = 
Low level 
N = 666 
Hs-cTnT 
(15-31ng/l) 
=moderate level   
Hs-cTnT (≥32ng/l) 
=high level   
N=1125 N=1648 
  OR 95% CI P value OR 95% CI P value 
Sum of the comorbidities 1.22 [1.16 ; 1.28] p<0.001 1.38 [1.31 ; 1.44] <0.001 
Old group  
[75-84 years old] 
2.03 [1.63; 2.52] p<0.001 2.13 [1.73; 2.63] <0.001 
Old-old group  
[≥ 85 years old] 
4.49 [3.10; 6.50] p<0.001 5.61 [3.92; 8.03] <0.001 
Young-old group  
[65-74 years old]  
1     1     
Reference group: 1, CI= confidence interval. Multivariate logistic regressions were performed to 
quantify the risk of having a high level of troponin according to age and comorbidities. 
 
More clearly, the odds ratios of 2.13 means that a patient aged between 65 and 74 years has 
2.13 times “risk” of being in the high level group compared to the moderate level group (2.03 
times) which might be interpreted  as the hs-cTnT value almost increases more with advancing 
age (p<0.001). 
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The same conclusion can be drawn with regard to the difference in odds ratios of 4.49 and 5.61 
means that a patient aged 85 years and more has a 4.49 times risk of being in the moderate 
level group compared to be in the high level troponin group (5.61) which could present the 
increased probability of having increased troponin level in old-old group (p<0.001). 
In women groups, like men groups, the odd ratio of the maximum increased troponin levels was 
shown in old-old group and old group respectively. 
Table VI. Odd Ratio in women, by considering age groups and comorbidities 
Female              
Reference category: 
Troponin (0-14ng/l) = 
Low level 
N = 860 
Hs-cTnT 
 
(15-31ng/l) 
=moderate level 
  
           Hs-cTnT 
 (≥32ng/l) 
=high level   
N=1176 N=1347 
  OR 95% CI P value OR 95% CI P value 
Sum of the 
comorbidities 1.23 [1.18 ; 1.28] p<0.001 1.26 [1.21 ;1.32] <0.001 
Old group  
[75-84 years old] 1.53 [1.25 ; 1.89] p<0.001 1.70 [1.37; 2.10] <0.001 
Old-old group  
[≥ 85 years old] 4.45 [3.47 ; 5.70] p<0.001 4.55 [3.53; 5.82] <0.001 
Young-old group  
[65-74 years old]  1     1     
Reference group: 1, CI= confidence interval. Multivariate logistic regressions were performed to 
quantify the risk of having a high level of troponin according to age and comorbidities. 
Similarly, in women group, the odds ratios of 1.70 means that a patient aged between 65 and 74 
years has 1.70 times “risk” of being in the high level group compared to the moderate level 
group (1.53 times) which might be interpreted  as the hs-cTnT value almost increases more with 
advancing age (p<0.001). 
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The same conclusion can be drawn with regard to the difference in odds ratios of 4.45 and 4.55 
means that a patient aged 85 years and more has a 4.45 times risk of being in the moderate 
level group compared to be in the high level troponin group (5.55) which could present the 
increased probability of having increased troponin level in old-old group (p<0.001). 
Definitely, with each increase in the number of comorbidity in women’s group ,the risk of having 
a moderate and high level of Hs-cTnT has shown to have increased by 1.23 [1.18; 1.28] and 
1.26 [1.21; 1.32]. 
In order to evaluate the effect of age and comorbidity burden on serum concentration of Hs-
cTnT, adjusted OR was included to our logistic regression model. 
Table VII- Adjusted Odds Ratio for one comorbidity and for a year of ageing 
     Tertile of hs-cTnT          AOR                      95% CI P value 
2      Burden of disease 
        Age 
1.216 
1.070 
[1.178, 1.255] 
[1.061,1.080] 
p<0.001 
p<0.001 
 
3      Burden of disease 
        Age 
1.311 
1.073 
[1.272, 1.352] 
[1.064, 1.082] 
p<0.001 
p<0.001 
       Reference category is: 1, CI= confidence interval. AOR= Adjusted Odds Ratio 
 
Apparently, advancing age and having comorbidity could increase the hs-cTnT levels, that 
means advancing age or presence of comorbidity elevate the chance of being in moderate 
troponin group(2)  or high troponin group(3),compare to the low troponin group(1), p<0é001). 
Surprisingly, with regards to the table of adjusted OR (Table VII), if we consider a year of aging 
and one comorbidity in continuous, so the OR of having raised troponin shows more influenced 
by having comorbidity, compare to ageing (adjusted OR for burden of disease 1.216 compare to 
age that is 1.070 in group 2, and adjusted OR for burden of disease 1.311 compare to age that 
is 1.073 in group 3), (p<0.001). 
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Statistical Conclusion 
Given above results, it is confusing that the figures25, 26, 29, and 30 show the level of troponin 
increases with advancing age, while the results from odds ratio, in the contrary show that 
patients aged 75 to 84 and 85 years and older were significantly more likely to have a moderate 
and high level of troponin than low compared to individuals aged 65 to 74 years. 
In other words, our sub-analysis demonstrated that in both sexes, the patients aged between 65 
and 74 years the mean (x̅) of Hs-cTnT values (the difference between the largest and the 
smallest values, [min; max]) is much bigger than the 75-84 age group and 85 and over. 
To make it clearer, similarly among women and men aged 65 to 74 aged, the extreme values of 
Hs-cTnT were found. It can be exemplified by an individual with an Hs-cTnT value of 9258 ng/l 
(which would probably be clinically correct) which could influence the Mean (x̅). 
The main disadvantage of the Mean (x̅) in statistical analysis refers to its susceptibility to the 
impact of outliners, so the Mean cannot be representative of the values in the sample. 
Therefore, in this situation, it would be preferred to have a more accurate measure of central 
tendency. In this case, from a statistical point of view, the use of the Median [Q1: 25 percentile; 
Q3: 75 percentiles] which is not influenced by extreme values, seems more precisely. 
By applying the median, it could be shown that the Hs-cTnT values increases with advancing 
age in both men and women (Table VI).The odds ratio was used to determine whether 
advancing age is a risk factor for an elevated cardiac troponin level, and to compare the 
magnitude of advancing age or effect of comorbidities for that outcome. 
As a brief reminder (Raydurg, et al.2016): 
OR/AOR=1 Exposure does not affect odds of outcome 
OR/AOR>1 Exposure associated with higher odds of outcome 
OR/AOR<1 Exposure associated with lower odds of outcome 
While interestingly, by driving AOR, the probability of having an elevated Hs-cTnT will relate to 
the presence of comorbidities, not advancing age (Table VII). In other words, ageing could not 
be a risk factor to increase cardiac troponin levels in elderly. 
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It could be concluded that among elderly patients, in both sexes, with abnormal cTnT values, 
older patients were more likely to have an elevated troponin level compared to the younger 
cohorts due to the presence of comorbidities, but not ageing (p<0.001). 
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Discussion: 
Although the hs-cTnT is a marker that has made a significant contribution to the diagnosis of 
myocardial acute events, the interpretation of abnormal hs-cTnT levels remain as a debate 
amongst geriatric cardiologists. It could become a challenging issue facing the elderly patients 
with vague ischemic symptoms, atypical ECG and abnormal cTnT levels, since that is proven 
that certain adverse outcome in acute coronary events increase with age (Ngako, et al, 2009). 
This study aimed to determine the influence of age on the value of hs-cTnT in older adults with 
one or more comorbidities to improve prediction of acute coronary events in elderly. 
The results of the present study, in elderly and very elderly patients suffering from different 
comorbidities, show that the presence of comorbidities compared with advancing age has more 
affect on hs-cTnT level. In contrast, the troponin rises in the absence of AMI or ACS resulted 
from the presence of comorbidities 
The main significant novelty of present study is to exclude acute cardiac events in order to 
eliminate the role of cardiac injury on increasing hs-cTnT levels, and to consider the 
comorbidities in sample pools as well. That means that the effects of advancing age and acute 
coronary events, as a confounding bias, are diminished. 
In our literature review, among the present comorbidities that have included in different studies, 
almost all papers indicated that the renal dysfunction and congestive heart failure are the reason 
of increased hs-cTnT values in geriatric patients (Mahajan, et al,2006;Lamb,  Webb,  & Abbas, 
2004 ;Freda, et al.,2002). 
In almost all previous similar studies where the individuals were screened to rule out ACS, the 
majority of these studies have justified the increased hs-cTnT level as related to the advanced 
age if the acute cardiac events could be excluded.Although in these studies the comorbidities 
were presented, the authors only indicated that the reason for increased hs-cTnT was levels 
related to advanced age(Missov., & De Marco, 1999;Ferri, 2010; Reiter,  Reichlin, Twerenbold, 
& Mueller, 2011;Zaman, et al.,2011;Carro, & Kaski,2011;Anderson, 2011;Covino, et al.,2012; 
Olivieri, et al.,2012;Rains, Laney, Bailey,  & Campbell, 2014;Gore, et al.,2014;Zeller, et 
al.,2015;Webb, et al., 2015).In other words, the age has been considered as a risk factor for 
elevated hs-cTnT,which means the hs-cTnT level is elevated by advancing age per se.  
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Although only a few studies have suggested the influence of comorbidities on raised hs-cTnT, 
they were more attributed to the effect of advancing age (Zethelius, Johnston, & Venge, 2006; 
Gravning, et al, 2014). Several studies have considered the influence of ageing on hs-cTnT is 
significant, consequently they have underestimated the diagnostic role of hs-cTnT assay in 
acute coronary event profiles (Lamb, Webb, & Abbas, 2004; Mahajan, et al., 2006). While, our 
data analysis could suggest a different interpretation of rising hs-cTnT levels in elderly, namely 
the hs-cTnT could still be a sensitive and very useful acute cardiac biomarker to detect acute 
coronary events, and could play a more significant role in ACS diagnosis in aged patients, 
mainly old-old patients if other reasons of its elevation are taken into consideration such as other 
causes (co-morbidities) of increased hs-cTnT levels.  
A study of factors affecting hs-cTnT values has shown that the hs-cTnT levels are higher in men 
and increases with age in both men and women (Noeller, et al., 2003).Our results fit with the first 
part of mentioned study, which means that the basic levels of hs-cTnT is increased in men 
compared to women, but controversially our evidences have shown that the hs-cTnT levels are 
not changed with age in both sexes.  
As the previous studies have significantly interpreted the elevated of hs-cTn values as an effect 
of advancing age (Missov., & De Marco, 1999; Ferri, 2010; Reiter, Reichlin, Twerenbold, & 
Mueller, 2011; Anderson, 2011; Olivieri, et al., 2012), our data analysis shows that the possible 
causes of the increased hs-cTnT in elderly population are due to the presence of different 
comorbidities, not only advancing age. While the elevated hs-cTnT values are considered as 
result of advancing age, it may be concluded that the hs-cTnT assay is not a reliable criterion to 
exclude or include acute cardiac events in diagnosis of geriatric patients. On the contrary, at the 
absence of a thrombotic complication of coronary artery disease in elderly patients, an elevated 
hs-cTnT value could be interpreted as a marker of undiagnosed concomitant disease, the “false 
positive rate” declines substantially. 
To our knowledge, this study is the first to document that advancing age has a less to play a role 
in elderly patients with high hs-cTnT concentrations. Based on the results of present study, the 
elevated levels of hs-cTnT in aged patients without any acute cardiac events is further due to 
other causes and less frequently from advancing age. 
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Conclusion 
It is shown that there is an overall increase of Hs-cTnT values in all groups of comorbidities. Our 
findings suggest that in elderly patients the association of elevated Hs-cTnT and advanced age 
is under question, so regardless of the presence of comorbidity, increased Hs- cTnT value 
should  be taken into account for the diagnosis of ACS  and should not divert attention from 
other underlying clinical problems. It is suggested that patients’ comorbidity should be taken into 
consideration when ruling out acute coronary events and/or adverse prognostic implications in 
patients who have very high hs-TnT concentrations. In other words, advanced age could not be 
associated to an elevation of Hs-cTnT; in contrast, cardiac troponin elevation is the result of pre-
existed comorbidities independently of their number. Increased troponin level in elderly should 
always be considered as pathological and a specific etiology searched. 
Study strengths 
In the current study, our sample size was extremely large, so in our statistical analysis the t-test 
has so much power that even a miniscule difference was flagged as statistically significant. On 
the other hand, we recruited the medical records of a large heterogeneous elderly populations, 
who were divided into three main aged group with seventeen comorbidities, so our results could 
be applied or generated to represent group of elderly patients, as a whole. This research study 
was unique, that can be concluded advancing age should not be considered as the only risk 
factor for raised hs-cTnT. 
Study Limitations 
In our study, the evaluation of hs-cTnT accuracy was limited since the data was collected only 
on elderly patients with different comorbidities, without having much awareness of their 
concomitant therapy. In other words, it is not possible to justify the presence of different 
comorbidity, how much it could increase the level of hs-cTnT values. Therefore, we cannot 
speculate the variance of the hs-cTnT values in elderly patients who were affected by different 
concomitant diseases with respect to their comorbidity. 
The other limitation of the current study is the lack of information about the patient’s medications 
and their medical history in our data base. 
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Lastly, in this study, although the data was included from a large cohort of patients, these data 
are observational, so further interventional studies are needed to detect the impact of each 
comorbidity with considering age and sex. 
Future directions 
Features of acute coronary events in elderly and very elderly patients comprise life-threatening 
conditions that require immediate and efficient medical intervention to improve prospective 
outcomes, particularly at the presence of atypical singes and symptoms. Judicious interpretation 
of increased hs-cTnT levels is particularly essential in different fields of medicine particularly in 
emergency wards, intensive care units and geriatric cardiology. Clinical assessment with use of 
para-clinical data is critical for an accurate and prompt diagnosis followed by appropriate 
management. Thoughtful interpretation of hs-cTnT levels may yield insight into physio- 
pathological mechanism of the concomitant condition that causes the raised hs-cTnT in elderly. 
Furthermore, future directions should aim to find the cut-off level for hs-cTnT levels at the 
presence of different comorbidities in acute coronary events, and study the relationship between 
mortality and increased levels of troponin in elderly patients with different comorbidities as well. 
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High level of cardiac Troponin T (hs-cTnT) in geriatric population has been considered as an age-related phenom-
enon, whichmay question the interpretation of the increase of hs-cTnT in this population. The challenge is what
is the primary cause of the increased hs-cTnT levels in elderly patients without AMI.
Objective: The aim of the current studywas to determine the impact of aging on hs-cTnT levels in elderly patients
without acute cardiac events but in the presence of comorbidities.
Methods: Sociodemographic and clinical data were collected from 6977 medical records of patients aged
≥65 years without acute coronary events but for whom hs-cTnT measurements were available. The patients
were stratiﬁed based on age, troponin levels and the number of comorbidities.
Results: The results suggested that the likelihood of increased hs-cTnT was related to the presence of comorbid-
ities independently of their number (p b 0.05). The adjusted odds ratio (AOR) for both advanced age and having
comorbidity was statistically signiﬁcant, however for the old group (74 ≥ age ≥ 84 years) the chance of having
elevated troponin regarding age compared to the presence of comorbidity was 1.070 vs. 1.216, whereas for the
old-old group (≥85 years) it was found to be 1.071 vs. 1.311. Besides statistical signiﬁcance for age, from a clinical
standpoint, the AOR of 1.070 may not be considered clinically relevant.
Conclusion: Increased hs-cTnT levels were associated with the presence of pre-existing comorbidities indepen-
dently of age. Increased hs-cTnT levels in the elderly should always be considered as pathological, and a speciﬁc
etiology should be searched.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Elderly patient,when experiencingmyocardial infarction, frequently
present with atypical symptoms, often lack chest pain, have non-
diagnostic ECG and delay in diagnosis and treatment [1]. High sensitiv-
ity troponin can aid in the rightful diagnosis of primary typemyocardial
infarction (type 1/associated with primary coronary event) when
interpreted appropriately. Making or excluding correctly a myocardial
infarction diagnosis in due time is paramount, especially in the elderly
population, since they are both prone to worse prognosis if left un-
treated and more complications from therapy than younger counter-
parts [2,3]. Correct interpretation of elevated troponin in the elderly
requires understanding of the factors that inﬂuence the baseline level
of that protein. Most of the available literature indicates a positive and
independent association with aging and increased baseline troponin
level, but few, if none, have compared directly the impact of aging itself
to the comorbidity burden that may come with aging [4–6].
Coronary heart disease (CHD) events are well established as a lead-
ing cause of death among older people [7], but the relationships be-
tween age, comorbidities and the levels of cardiac biomarkers serving
as indicators for cardiac events are still subject to debate. One such bio-
marker, cardiac troponin, is established as the best biomarker to detect
myocardial necrosis [8].
With the growing clinical adoption of cardiac troponin, the diagnosis
of acute myocardial infarction (AMI), or acute coronary syndrome
(ACS), has shifted from a primarily clinical diagnosis predicated on elec-
trocardiogram (ECG) ﬁndings and blood biomarker levels, to one essen-
tially based on cardiac troponin assays, supported by clinical and ECG
ﬁndings [9].
The importance of cardiac troponin becomes even more prominent
in elderly patients [8], particularly those N80 years of age, forwhom sec-
ondary diagnostic characteristics of ACS such as chest pain, electrocardi-
ography, and biomarkers are often unreliable when trying to exclude
AMI [10]. This is exacerbated by the high prevalence of multiple chronic
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conditions and comorbidities in elderly patients, which may result in
“atypical” or “asymptomatic” presentations [11]. There is, however,
only limited data about cTnT behavior in elderly patients, and even
less knowledge about cTnT in the oldest bracket of patients with AMI
in the presence of comorbidities [12]. Moreover, hs-cTnT assays have
been shown to be associated with a higher frequency of false-positives
for AMI in elderly patients [13]. As such, AMI misdiagnoses are frequent
with very old patients [14] and an improved interpretation of elevated
hs-cTnT in elderly patients with comorbidities could have a consider-
able inﬂuence on ACS risk stratiﬁcation.
Our hypothesis is that, after excluding ACS in elderly patients, the in-
creased cardiac troponin values aremainly associatedwith the presence
of comorbidities and not with age. Therefore, the main objective of this
research is to determine the differential effect of age and comorbidities
on the increased plasma hs-cTnT levels in elderly patients without ACS.
2. Methodology
2.1. Patients selection and database records
This retrospective observational cohort study in geriatric Caucasian
population was undertaken at the University Hospital of Sherbrooke
(Quebec, Canada) (CHUS) using administrative database of patient re-
cords. Selected patients were aged ≥65 years, admitted to the university
hospital between January 2012 and December 2016 and for whom se-
rial analysis of hs-cTnT levels had been performed. Patient records
were reviewed, and demographic, clinical and hs-cTnT data were
extracted.
Data records were obtained for all patients admitted for emergency
evaluation suspecting acute coronary events (chest pain, sweeting, pal-
pitations, vomiting, dyspnoea). The exclusion of ACS was based on the
same diagnostic criteria applied in our hospital, namely, the serial mea-
surement of hsTnT (0, 2 h and 6 h) and also the ECG. The ﬁrst statistical
step of analysis contained 7080 medical records. The database was re-
ﬁned by detecting and or removing corrupt, inaccurate, or unnecessary
records from our data pool. Our reﬁned data thenwas reduced to a sam-
ple of 6822medical recordswith the presence ofmultiple comorbidities
in all. The study protocol was approved by the local Ethical Committee
of the CIUSSS de l'Estrie-CHUS (approbation # 2018-2441).
2.2. Variables
The main dependent variables were hs-cTnT values and the occur-
rence of the following concomitant comorbidities: diabetes, heart fail-
ure (HF), chronic obstructive pulmonary disease (COPD), renal
insufﬁciency, cancers, hypertension, neurocognitive disorders, hypo-
thyroidism, anemia, cardiomyopathy, pulmonary hypertension, pulmo-
nary embolism, pneumonia, stroke, atherosclerotic vascular disease,
subarachnoid hemorrhage and other non-acute cardiovascular disease.
Demographic and independent variables were age and sex.
2.3. Hs-cTnT assay
The hs-cTnT was measured using the elecrochemiluminescence im-
munoassays with Roche Elecsys analyzers (Troponin T Stat, Roche Diag-
nostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland), with a limit of
detection of 3 ng/L.
All patients for whom the diagnosis was MI or ACS have been auto-
matically excluded. Therefore, for the included patients only theﬁrst hs-
cTnT measurement, collected at time of admission to the hospital or
emergency department, was considered.
2.4. Statistical analysis
Continuous variables were expressed as means ± standard devia-
tion (SD), median and quartiles. Categorical variables were expressed
as absolute values and percentages of the total. Independent t-test (to
compare the troponin levels between age groups), Chi-square tests or
Pearson χ2 tests (to evaluate the differences in the prevalence of comor-
bidities according to troponin levels) and multivariate logistic regres-
sion (to determine the association between the risk of having high
troponin levels with age and comorbidities) were applied. Data were
analyzed using SPSS (v24; IBM, USA). The statistical signiﬁcance level
was set at P b 0.05.
3. Results
A total of 6977 medical records of patients aged ≥65 years were in-
cluded in the study database. After excluding all medical records with
a history of cardiac arrest, previous or post-operative AMI and/or miss-
ing medical information, a ﬁnal sample of 6822 elderly patients
remained.
Table 1 presents the demographic and clinical characteristics of the
study cohort. The cohortwas categorized into three age groups: patients
aged 65 to 74 years (young-old), aged 75 to 84 years (old) and aged
≥85 years (old-old). The average age of our sample was 78.3 years,
with the oldest patient aged 104 years. Subjects were also divided into
three categories according to the tertile of hs-cTnT concentration:
tertile 1 (0–14 ng/L= low level: normal, according to themanufacturer
instructions), tertile 2 (15–31 ng/L = moderate level) and tertile
3 (≥32 ng/L = high level). Themeanhs-cTnT level in our total sample
was 79.9 ng/L.
The cohort was further categorized according to the occurrence of
comorbidities: quartile 1 (one or two comorbidities), quartile 2 (three
comorbidities), quartile 3 (four or ﬁve comorbidities) and quartile
4 (≥6 comorbidities). A large number of subjects (n = 2414; 35.4%)
had six or more comorbidities. Arterial hypertension and cardiomyopa-
thy were the most and the least frequently observed comorbidities,
respectively.
Table 2 presents total and by-sex mean hs-cTnT levels according to
the comorbidity quartiles. The standard deviation of total and all quar-
tile from the mean of troponin level was found relatively high due to
the dispersion of troponin values. The mean hs-cTnT was considered
high across sexes, age groups and comorbidity quartiles.
Table 1
Demographic and clinical characteristics of the study cohort.
Age: x ̅± SD 65–74 years old
(n= 2555)
69 ± 2.83
75–84 years old
(n= 2490)
79 ± 2.88
≥85 years old
(n= 1777)
89 ± 3.62
All patients
(n= 6822)
78.3 ± 8.30
Men (%) 1456 (57%) 1294 (52%) 649 (36%) 3439 (50.4%)
Women (%) 1098 (43%) 1196 (48%) 1128 (64%) 3383 (49.6%)
Hs-cTnT ng/L
(x ̅± SD)
93 ± 312.15 77 ± 234.46 63 ± 162.73 79 ± 252.14
Men 104 ± 353.0 80 ± 183.73 70 ± 125.32 89 ± 264.64
Women 78 ± 242.34 74 ± 279.19 59 ± 180.71 70 ± 238.45
Comorbidities
(N, %)
Quartile I
(1291, 19.4)
Men 283.48 228.52 132.61 643.48
Women 349.52 207.48 83.49 684.52
Quartile II
(1048, 15.4)
Men 169.39 188.48 149.58 506.48
Women 263.61 204.52 78.42 545.52
Quartile III
(2030, 19.8)
Men 313.41 355.48 354.67 1022.51
Women 442.59 392.52 174.33 1008.49
Quartile IV
(2414, 35.4)
Men 294.43 425.46 493.61 1212.51
Women 397.56 491.54 314.39 1202.49
Hs-cTnT (High-sensitivity cardiac Troponin T), ng/L = nanogram/L Quartiles (I = 1–2
comorbidities, II = 3 comorbidities, III = 4–5 comorbidities, IV = ≥6 comorbidities).
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According to our primary data analysis, the probability of having
raised levels of troponin was increased with all types of comorbidities.
In our pooled analysis of patients' medical records, plasma levels of
hs-cTnT had a non-parametric distribution as the hs-cTnT values were
abnormally distributed. In other words, the level of hs-cTnT was
extremely dispersed above the reference range, that means a lot of pa-
tients had raised hs-cTnT level N33 ng/Lwhereas the standard deviation
thatwas of greatermagnitude than itsmean. It can be exempliﬁed by an
individual with an Hs-cTnT value of 9258 ng/L (which would probably
be clinically correct) which could inﬂuence the Mean (x̅).
By analyzing hs-cTnT across age groups when corrected for comor-
bid disease there was a signiﬁcant decrease of baseline hs-cTnT in
male patients and an insigniﬁcant trend in female patients (Table 3).
When participants with elevated Hs-cTnTwere compared with par-
ticipants with troponin levels within the reference range using the ad-
justed odds ratio, there was a signiﬁcantly increased probability of
having an increased level of troponin in the moderate or high-level
range that came with age but also with each comorbidity (Table 4).
For example, male participants of N84 years old had a crude odds ratio
of 5.61 (p b 0.001) for having an increased level of hs-cTnT but this
did not account for comorbid diseases of that group (Table 4).
In order to determine whether the observed increases in troponin
were attributable to advancing age or the occurrence of comorbidities,
adjusted OR (AOR) were included into our logistical regression model
(Table 5). By analyzing the risk of having increased troponin
levels with the adjusted odds ratio (AOR) still taking the population
with normal troponin levels as the reference range, the relative impact
of each added comorbidity surpasses the effect of one year of aging as
shown in Table 4. Each year of aging confers an AOR of having a
high level of hs-cTnT of 1.073 (p b 0.001) which is far less than the
impact of one added comorbid disease which confers an AOR of 1.311
(p b 0.001).
The main disadvantage of the mean (x̅) in statistical analysis refers
to its susceptibility to the impact of outliners, so the mean cannot be
representative of the values in the sample. Therefore, in this situation,
it would be preferred to have a more accurate measure of central ten-
dency. In this case, from a statistical point of view, the use of theMedian
[Q1: 25 percentile; Q3: 75 percentiles] which is not inﬂuenced by ex-
treme values, seems more precise. Therefore, we applied the median
to present Hs-cTnT values (interquartile range).
The occurrence of more comorbidity appears to have a greater inﬂu-
ence on troponin levels, compared to age, in both hs-cTnT tertiles. In
other words, among the elderly, age may not be a risk factor for in-
creased cardiac troponin levels.
4. Discussion
Although the hs-cTnT is a marker that has made a signiﬁcant con-
tribution to the diagnosis of acute myocardial events, the interpreta-
tion of abnormal hs-cTnT levels remain as a debate among geriatric
cardiologists. It could become a challenging clinical issue for the
elderly patients with vague ischemic symptoms, atypical ECG and
Table 2
Levels of hs-cTnT (ng/L) by sex and comorbidity quartiles.
Total (X ̅± SD) Men (X ̅± SD) Women (X ̅± SD) P-value
Q I 79 ± 324.68 93 ± 416.20 65 ± 181.78 p N 0.05
Q II 81 ± 290.86 89 ± 263.39 71 ± 317.80 p N 0.05
Q III 89 ± 264.02 97 ± 242.62 81 ± 283.43 p N 0.05
Q IV 71 ± 161.85 66 ± 203.50 76 ± 119.84 p N 0.05
Quartiles (I = 1–2 comorbidities, II = 3 comorbidities, III = 4–5 comorbidities, IV = ≥6
comorbidities), Hs-cTnT (High-sensitivity cardiac Troponin T), SD (standard deviation).
Table 3
Median and quartiles of hs-cTnT, by sex and age.
Male Female
Median [Q1; Q3] Median [Q1; Q3]
65–74 years 24.0 [13.0; 57.2] 19,0 [9.0; 45.2]
75–84 years 33.0 [19.0; 63.0] 24,0 [14.0; 48.0]
85+ years 39.0 [25.0; 67.2] 31,0 [20.0; 52.0]
Q1: 25 percentile; Q3: 75 percentiles.
Table 4
Odd ratios of having moderate or high levels of hs-cTnT in men and women, by age groups and the occurrence of comorbidities.
Hs-cTnT (0-14 ng/L) = Low level Hs-cTnT (15-31 ng/L) = moderate level Hs-cTnT (≥32 ng/L) = high level
Men N= 666 N= 1125 N= 1648
Women N= 860 N= 1176 N= 1342
OR 95% CI P value OR 95% CI P value
Sum of the comorbidities for men 1.22 [1.16; 1.28] p b 0.001 1.38 [1.31; 1.44] p b 0.001
Sum of the comorbidities for women 1.23 [1.18; 1.28] p b 0.001 1.26 [1.21; 1.32] p b 0.001
Old group [75–84 years old]
Men 2.03 [1.63; 2.52] p b 0.001 2.13 [1.73; 2.63] p b 0.001
Women 1.53 [1.25; 1.89] p b 0.001 1.70 [1.37; 2.10] p b 0.001
Old-old group [≥85 years old]
Men 4.49 [3.10; 6.50] p b 0.001 5.61 [3.92; 8.03] p b 0.001
Women 4.45 [3.42; 5.70] p b 0.001 4.55 [3.53; 5.82] p b 0.001
Young-old group [65–74 years old]
Men 1 1
Women 1 1
Reference group: 1, CI = conﬁdence interval. Multivariate logistic regressions were performed to quantify the risk of having a high level of troponin according to age and comorbidities.
For both the old and old-old age groups and for both sexes, we observed a greater risk of having higher levels of hs-cTnT. After calculating odds ratio, with each increase in age, in all age
groups of both sexes, the risk of having a moderate and high level of hs-cTnT has shown to be increased.
Table 5
Adjusted odds ratio for one comorbidity and for a year of aging.
Tertile of hs-cTnT AOR 95% CI P value
2
Burden of disease 1.216 [1.178, 1.255] p b 0.001
Age 1.070 [1.061, 1.080] p b 0.001
3
Burden of disease 1.311 [1.272, 1.352] p b 0.001
Age 1.073 [1.064, 1.082] p b 0.001
Reference category is: 1, CI = conﬁdence interval. AOR = adjusted odds ratio.
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abnormal cTnT levels, to diagnose whether the patient suffer from
ACS, since it is proven that certain adverse outcomes due to acute
coronary events increase with age [15].
This study aimed to determine the inﬂuence of age on the value of
hs-cTnT in older adults without acute cardiac events, but with one or
more comorbidities, to improve the diagnostic prediction of acute coro-
nary events in elderly.
The results of the present study have shown that, in elderly and very
elderly patients suffering from different comorbidities, the presence of
comorbidities compared with advancing age has more effect to rising
hs-cTnT level. In other words, the raised cardiac troponin in the absence
of AMI or ACS in the elderly population resulted from the presence of co-
morbidities and not from their age.
The main signiﬁcant novelty of the present study is to exclude acute
cardiac events (ACE) in order to eliminate the role of cardiac injury on
increasing hs-cTnT levels, and to consider the comorbidities in the sam-
ple pools as well. That means that the effects of advancing age and ACE,
as confounding biases, are diminished.
In our literature review, among the comorbidities that have been in-
cluded in the different studies, almost all papers indicated that the renal
dysfunction and congestive heart failure are themain reasons for the in-
creased hs-cTnT values in geriatric patients [16,17].
In almost all previous similar studies where the individuals were
screened to rule out ACS, the majority of these studies have justiﬁed
the increased hs-cTnT level as related to the advanced age if the ACS
could be excluded. Although in these studies the comorbidities were
presented, the authors only indicated that the reason for the increased
hs-cTnT levels was the advanced age [8,18–25]. In other words, the
age has been considered as the main factor for explaining the elevated
hs-cTnT.
Although a few studies have suggested the inﬂuence of comorbidi-
ties on raised hs-cTnT, theywere still more attributed to the effect of ad-
vancing age [26]. Several studies have considered the inﬂuence of age
on hs-cTnT as signiﬁcant; consequently, they have underestimated the
diagnostic role of hs-cTnT assay in ACE proﬁles [16,17]. While, our
data analysis suggests a different interpretation of the rising hs-cTnT
levels in elderly, namely the hs-cTnT could still be a sensitive and very
useful acute cardiac biomarker to detect acute coronary events, and
could play a more signiﬁcant role in ACS diagnosis in aged patients,
mainly in old-old patients if other reasons of its elevation are taken
into consideration such as other causes (co-morbidities) leading to in-
creased hs-cTnT levels.
A study of factors affecting hs-cTnT values has shown that the hs-
cTnT levels are higher in men and increases with age in both men and
women [27]. Our results ﬁt with the ﬁrst part of mentioned study,
which means that the basic levels of hs-cTnT are increased in men
compared to women, but in contrast our results have shown that the
hs-cTnT levels are not showing clinically signiﬁcant change with ad-
vancing age in both sexes.
As the previous studies have signiﬁcantly interpreted the ele-
vated of hs-cTnT values as an effect of advancing age [13,19], our
data analysis shows that the possible causes of the increased hs-
cTnT in elderly population are the presence of different comorbidi-
ties, and not advancing age. Our results are also not in agreement
with those of Kuster et al. showing that hs-cTnT concentration, inde-
pendently of comorbidities, increases exponentially with age after
65 years [6]. However, in their study the authors had used Cox
regression to analyze their data which was not possible in our condi-
tion due to abnormal distribution of the hs-cTnT values. If the ele-
vated hs-cTnT value considered as a result of advancing age, it may
be assumed that the hs-cTnT assay is not a reliable criterion to ex-
clude ACE in diagnosis of geriatric patients. However, at the absence
of a thrombotic complication of coronary artery disease in elderly
patients, an elevated hs-cTnT could be the result of undiagnosed co-
morbidities. Considering our pool of patients, it could be concluded
that among elderly patients of either sex, with abnormal hs-cTnT
values, older patients were more likely to have an elevated troponin
level compared to the younger cohorts due to the presence of comor-
bidities, but not to age (p b 0.001).
To our knowledge, this is the ﬁrst study to document that advancing
age has a less role to play in elderly patients with high hs-cTnT concen-
trations. Based on the results of the present study, the elevated levels of
hs-cTnT in aged patients without any ACE are further due to other
causes which should be thoroughly investigated.
5. Conclusion
It is shown that there is an overall increase of hs-cTnT values in all
groups of elderly patients with comorbidities. Our ﬁndings suggest
that in elderly patients the association of elevated hs-cTnT is mostly ex-
plained by the presence of comorbidity than by advancing age. Conse-
quently, an increased hs-cTnT value in an elderly subject that is not
associated to the occurrence of ACS should be always be investigated
for other underlying clinical problems.
6. Study strengths
In the current study, our sample size was large, so in our statistical
analysis the t-test has so much power that even a minuscule difference
was ﬂagged as statistically signiﬁcant. On the other hand, we recruited
the medical records of a large heterogeneous elderly population, who
were divided into three main aged groups with seventeen comorbidi-
ties, so our results could be applied or generated to represent group of
elderly patients, as a whole. Thus, the main result of the study showing
that age is not the main cause for hs-cTnT can be most probably
generalized.
7. Study limitations
In our study, the evaluation of hs-cTnT accuracy was limited since
the data was collected only on elderly patients with different comorbid-
ities, without having much awareness of their concomitant therapy. In
other words, it is not possible to quantify the presence of different co-
morbidity, how much it could increase the level of hs-cTnT values.
Therefore, we cannot speculate the variance of the hs-cTnT values in el-
derly patientswhowere affected by different concomitant diseaseswith
respect to their comorbidity.
Lastly, in this study, although the datawere included froma large co-
hort of patients, these data are observational.
8. Future directions
Features of acute coronary events in elderly and very elderly pa-
tients comprise life-threatening conditions that require immediate
and efﬁcient medical intervention to improve prospective outcomes,
particularly in the presence of atypical signs and symptoms. Judi-
cious interpretation of increased hs-cTnT levels is essential in differ-
ent ﬁelds of medicine, particularly in emergency wards, intensive
care units and geriatric cardiology. Clinical assessment with use of
para-clinical data is critical for an accurate and prompt diagnosis
followed by appropriate management. Thoughtful interpretation of
hs-cTnT levels may yield insight into physio-pathological mecha-
nism of the concomitant condition that causes the raised hs-cTnT
in elderly. Furthermore, future directions should aim to ﬁnd the
cut-off level for hs-cTnT levels at the presence of different comorbid-
ities in acute coronary events, and study the relationship between
mortality and increased levels of troponin in elderly patients with
different comorbidities as well.
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